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ABSTRACT
THE EFFECTS OF ANTIBODIES IN DISEASE PROGRESSION OF MOGINDUCED EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
by
Melissa Marie Riter
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Professor Jerri-Annette Lyons
Abstract: Multiple sclerosis (MS) is an auto-inflammatory disease of the central
nervous system (CNS), affecting over 400,000 people in the US. MS is primarily
studied in the animal model experimental autoimmune encephalomyelitis (EAE).
MS is a T cell mediated disease but there is mounting evidence for a role for B
cells in MS. Previous studies have established that rMOG Induction depends on
the presence of B cells, while induction using the MOG peptide covering amino
acids 35-55 does not require B cells to cause disease. When plasma from the
rMOG and MOG35-55 immunized WT mice was analyzed by ELISA there
binding at MOG21-45, covering the encephalogenic epitope, and binding
covering the MOG46-85 amino acids, which was not expected. This epitope was
observed again in T cells when comparing the WT and B cell -/- mice. WT T cells
only bound MOG35-55 but T cells from B cell-/- mice also bound MOG61-85. The
same epitope observed in WT antibodies. This led to the conclusion that this was
a cryptic epitope and seemed to produce an anti-inflammatory response. Mice
coimmunized with both MOG35-55 and MOG61-85 similar results were observed
as in rMOG immunization. Coimmunized mice had less severe disease than
those immunized with just MOG35-55 giving further evidence that MOG61-85
ii

produces a protective response. When rMOG immunized B cell -/- mice were
given serum from rMOG primed WT mice clinical disease could be observed.
This was also true for coimmunized mice. Meaning it was B cell products in the
serum not the B cells themselves that was altering the immune response. When
serum from MOG35-55 and MOG61-85 primed rabbit serum was used after heat
inactivation, WT and B cell -/- mice showed more severe disease. B cell -/- mice
given the immune serum also had an earlier onset of disease. This demonstrated
that the most likely cause of the altered response was antibody. Cells from mice
coimmunized injected with either immune rabbit serum or preimmune rabbit
serum were cultured with MOG35-55 and MOG61-85, proliferation was
measured. The mice in the preimmune group had greater proliferation to both
peptides. This may be because the encephalogenic cells had already migrated to
the CNS in the immune group. When T cells were cultured again with purified
antibody, from rMOG primed mice, proliferation decreased in all the wells with
antibody added, but when injected into coimmunized mice similar disease was
observed as seen in the mice given immune serum. Over all these results
indicate a role for antibody in the processing and presentation of MOG in EAE.
This may be through the suppression of the presentation of MOG61-85 when
antibody is bound to MOG when it is taken up by antigen presenting cells.
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Chapter I: Introduction
Multiple Sclerosis and Animal Model of Disease
Multiple sclerosis (MS) is a neurodegenerative, inflammatory disease of
the central nervous system (CNS). MS affects 400,000 people in the United
States and over 2.5 million worldwide (Smyth, 2011; Steinman, 2014). The
etiology of MS is not fully understood, but studies have demonstrate that both
genetic and environmental factors are important for disease development. Twin
studies reveal a 25% concordance (Compston & Coles, 2008; Willer, et al., 2003)
and there are studies linking 52 different genes to the development of MS, such
as those for the major histocompatibility complex (MHC) (Gourraud, Harbo,
Hauser, & Baranzini, 2012), and cytokines like interleukin-18 (Celik, et al., 2014).
On the other hand, environmental factors associated with MS have ranged from
diseases, such as Epstein Barr virus and measles (Sundqvist, et al., 2012), to
cigarette smoking (Jafari & Hintzen, 2011) and vitamin D deficiency (BerlangaTaylor, Disanto, Ebers, & Ramagopalan, 2011). How these different factors lead
to the development of MS is unknown.
MS patients can suffer from a variety of symptoms including pain,
paralysis, balance problems, and bladder dysfunction (Fletcher & Mills, 2012).
How the disease progresses will depend on the type of MS, and which symptoms
occur will depend on where in the CNS the lesions occur (Noonan, et al., 2010).
The two main types of MS are primary progressive MS (PPMS) and relapsing
remitting MS (RRMS) (Noonan, et al., 2010; Smyth, 2011). 85% of MS patients
present with RRMS, while only 15% present with PPMS (Noonan, et al., 2010).
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PPMS exhibits a linear disease course. These patients may have plateaus in
disease progression but once a symptom occurs, it becomes permanent. RRMS
patients have intermittent disease and early in the disease course will fully
recover from all symptoms during a remission. These relapses occur once every
few years and last days to weeks (Steinman, 2014). Relapses are defined as a
neurological change that lasts for at least 24 hours; not brought on by changes in
body temperature (Steinman, 2014). Eventually these patients will no longer fully
recover and symptoms become permanent. Patients may still have periods of
remission, but disease progression may also change to a more linear disease
course. At this point these patients would be considered secondary progressive
MS patients (SPMS). About 50% of RRMS patients will progress to this stage
(Smyth, 2011). There are treatments available for patients with RRMS, which
slow disease progression, however, there is no effective treatment for PPMS or
SPMS patients currently available (Cross & Waubant, 2011; Leary & Thompson,
2005).
Clinical signs and symptoms of MS are caused by the development of
plaques, or lesions, within the CNS. These plaques can be classified into four
different types based on the cells and soluble proteins present. Types I, II, and
III are characterized by the predominance of macrophages and T cells
contributing to inflammation near the blood brain barrier (Lucchinetti, et al.,
2000). Type I and II are separated by the presence of immunoglobulins and
complement found primarily in type II plaques (Lucchinetti, et al., 2000; Serres, et
al., 2009; Quintana, et al., 2008). Microglia contribute to inflammation in type III
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plaques and are further separated by the diffuse inflammation observed with
oligodendrocytes undergoing apoptosis (Lucchinetti, et al., 2000; Marik, Felts,
Bauer, Lassmann, & Smith, 2007). Type IV also has diffuse inflammation and like
type III, and DNA fragmentation is observed, but other signs of apoptosis are not
seen (Lucchinetti, et al., 2000). Type III and IV do not show remyelination, unlike
type I and II lesions where remyelination is observed (Lucchinetti, et al., 2000;
Marik, Felts, Bauer, Lassmann, & Smith, 2007). The T cells found in different
lesions of MS patients have different V-D-J junctional regions of the T cell
receptor (TCR), which determine the specificity of the T cell (Friese & Fugger,
2009; Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012).This indicates that
each lesion has the expansion of a different T cell clone producing a new
population of specific T cells causing the damage within a single lesion.
The myelin sheath protects the axons of nerve cells and increases
conductivity of nerve signals. In MS the myelin sheath is damaged, exposing the
axon to damage and decreasing the conductivity of nerve signals. The sheath is
a complex mixture of lipids (70%) and protein (30%). Three myelin proteins
relevant to MS include: myelin basic protein (MBP), proteolipid protein (PLP), and
myelin oligodendrocyte glycoprotein (MOG). MS patients produce an immune
response to all three of these proteins (Greer, Cameron, McCombe, Good, &
Pender, 1997; Meinl, et al., 1997; Hjelmström, Penzotti, Henne, & Lybrand,
1998). MBP and PLP are the most abundant proteins in the CNS but they are not
exposed to the environment (Greer, Cameron, McCombe, Good, & Pender,
1997; Meinl, et al., 1997; Goverman J. M., 2011). Unlike MBP and PLP, MOG is
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a transmembrane protein, which means that part of the protein is readily
available for recognition by the immune system before any damage has been
done to the myelin sheath, making it a prime candidate for the initiation of the
autoimmunity characteristic of MS (Weber, Hemmer, & Cepok, 2011; Kursula,
2008).
All three of these myelin proteins are used to induce experimental
autoimmune encephalomyelitis (EAE), an animal model of MS. EAE is used to
study the immune mechanisms of MS (van der Star, et al., 2012). The EAE
model produces a disease similar to MS. The disease can be triggered by a
single T cell clone specific to an epitope on a myelin protein, but the response
can spread to other epitopes on the same protein or to epitopes on other myelin
proteins (Zamvil, et al., 1985; Lehmann, Fursthuber, Miller, & Sercarz, 1992).
The protein or peptide of protein is used to induce disease in susceptible animals
(i.e. mice, marmosets, and rats) with the appropriate adjuvant. The protein or
peptide used depends on the species and strain of animal being utilized (Lyons
J.-A. , Ramsbottom, Mikesell, & Cross, 2008; van der Star, et al., 2012). Disease
may also be induced using the passive transfer of immune cells or immunization
with appropriate protein and serum from animals immunized with the appropriate
protein in susceptible animals (Lyons, Ramsbottom, & Cross, 2002; van der Star,
et al., 2012). This biggest criticism of the EAE model is that the disease in not
spontaneous, but must be induced. Neither MS nor an MS-like disease occurs
naturally in animals, but disease can develop spontaneously in mice genetically
modified with transgenetic T cell receptors specific for MBP, but disease only
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occurs under non-sterile conditions (Goverman, et al., 1993; Lafaille, Nagashima,
Katsuki, & Tonegawa, 1994)

The Immune Response in MS/EAE
Effector CD4+ T cells

The immune response observed in MS was originally thought to be
mediated by type 1 helper T (Th1) cells but this has been challenged with the
discovery of Th17 cells. Th1 cells produce a T cell-mediated proinflammatory
response through the production of proinflammatory cytokines like interferon
(IFN)- ɣ. IFN-ɣ induces relapses in MS patients suggesting that an increase in
Th1 cells may induce relapses in relapsing remitting MS (Steinman, 2014). Th1
cells infiltrate the CNS and attract macrophages and natural killer cells to the
CNS where they are activated, causing the release of more proinflammatory
cytokines such as IFN-ɣ and tumor necrosis factor-α (TNF-α), which is toxic to
oligodendrocytes (Hedegaard, et al., 2008). However, mice lacking IFN-ɣ or TNFα had worsened disease in EAE this information, led to the discovery of a role for
Th17 cells in the pathology of disease (Steinman, 2014). Th17 cells also infiltrate
the CNS in MS and have been observed in the cerebral spinal fluid of MS
patients along with elevated levels of interleukin (IL)-17, the main cytokine
produced by Th17 cells (Komiyama, et al., 2006; Matusevicius, et al., 1999).
These cells are also implicated in the pathology of EAE (Kreymborg, et al., 2007;
Komiyama, et al., 2006). IL-17 is known to disrupt the blood brain barrier
(Compston & Coles, 2008). Furthermore Th17 cells recruit neutrophils to the
CNS which, and like macrophages, can cause further damage (Fletcher, Lalor,
Sweeney, Tubridy, & Mills, 2010). Both Th1 and Th17 cells are able to induce
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EAE through the passive transfer of cells from immunized mice, but appear to do
so through independent but complementary mechanisms (Fletcher, Lalor,
Sweeney, Tubridy, & Mills, 2010). IFN-β ameliorates Th1 induced disease but will
worsen Th17 induced disease (Fletcher, Lalor, Sweeney, Tubridy, & Mills, 2010).
The ratio of Th1 and Th17 cells differ in the spinal cord of mice with EAE, but
infiltration of the brain occurs when the Th17 cells outnumber the Th1 cells
(Steinman, 2014). It’s thought that Th1 cells enter the brain first and these cells
drive the MS-like disease and Th17 cells come later in the disease (Steinman,
2014).
Cytotoxic T cells

Cytotoxic T cells (CD8+) like CD4+ helper T cells are found in the plaques
of MS patients (Friese & Fugger, 2009; Fletcher, Lalor, Sweeney, Tubridy, &
Mills, 2010). CD8+ T cells produce cytotoxic products, such as perforin and
granzyme B; produce proinflammatory cytokines, such as TNF-α and IFN-ɣ; have
cytolytic activity; and activate myelomonocytic cells (Friese & Fugger, 2009).
CD8+ T cells cannot induce lysis in oligodendrocytes, but the myelomonocytic
cells, with both monocytic and granulocytic characteristics can induce lysis in the
oligodendrocytes, which produce the protective myelin sheath (Friese & Fugger,
2009). The amount of axonal damage in acute MS lesions has been correlated
to the number of cytotoxic T cells infiltrating the lesions (Friese & Fugger, 2009;
Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012; Saxena, Martin-Blondel,
Mars, & Liblau, 2011). There is also evidence that specific cytotoxic T cell clones
migrate to the CNS in patients with MS, which then undergo further expansion
(Friese & Fugger, 2009; Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012). In
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EAE cell transfer experiments, cytotoxic T cells have demonstrated the ability to
induce disease (Friese & Fugger, 2009). It is unknown if cytotoxic T cells are part
of the initiation of MS, but they appear to have a role in disease progression
through their cytokine production in active MS lesions (Friese & Fugger, 2009).
Regulatory T cells

Several different subsets of CD4+ and CD8+ regulatory T cells have been
identified (Correale & Villa, 2010). Both types of regulatory T cells suppress the
immune response through cell-to-cell interaction and the production of antiinflammatory cytokines (Filaci, Fenoglio, & Indiver, 2011). CD8+ regulatory T
cells can also regulate the immune response through cytotoxic mechanisms that
are not fully understood (Tejera-Alhambra, et al., 2012; Filaci, Fenoglio, &
Indiver, 2011). These cells are difficult to identify as they are present in smaller
numbers than effector T cells; do not proliferate as much as effector T cells in
response to stimulation; and there is no marker that identifies all regulatory T
cells (Fallarino, et al., 2003; Filaci, Fenoglio, & Indiver, 2011). Both CD4+ and
CD8+ regulatory T cells can be identified through the expression of the
transcription factor forkhead box p3 (FOXP3), but not all CD8+ regulatory T cells
are FOXP3 positive (Filaci, Fenoglio, & Indiver, 2011; Hu, Weiner, & Ritz, 2013).
Only about half of the identified CD8+ regulatory T cell subsets are FOXP3
positive (Filaci, Fenoglio, & Indiver, 2011) Two separate populations of CD4+
regulatory T cells produce the anti-inflammatory cytokines IL-10 (inducible
regulatory T cells) and transforming growth factor (TGF)-β (Th3 cells) (Fletcher,
Lalor, Sweeney, Tubridy, & Mills, 2010). TGF-β is a pleiotropic cytokine, the
function of which is dependent on the context in which it is expressed. On its
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own, TGF-β inhibits T cell proliferation, promotes regulatory T cell differentiation
and may promote cell death (Travis & Sheppard, 2014; Bettelli, et al., 2006).
However, in the presence of other cytokines like IL-2 cell death is inhibited and in
the presence of IL-6, TGF-β promotes Th17 cell differentiation (Travis &
Sheppard, 2014). CD4+ regulatory T cells suppression of effector T cells through
cells-to-cell contact appears to be antigen specific, but this does not appear to be
true for the CD8+ regulatory T cells (Sakaguchi, Wing, Onishi, Prieto-Martin, &
Yamaguchi, 2009; Hu, Weiner, & Ritz, 2013).
It has long been known that healthy individuals harbor myelin-reactive T
cells. Why these cells remain quiescent in these individuals but are activated and
lead to pathology in MS patients has long been a topic of investigation. Recent
studies have found that CD4+ regulatory T cells from MS patients appeared to
have less suppressive power than healthy controls when challenged in vitro and
in vivo (Fletcher, Lalor, Sweeney, Tubridy, & Mills, 2010; Steinman, 2014; Korn,
et al., 2007). Viglietta, Baecher-Allan, Weiner, and Hafle found that an ongoing
immune response in healthy controls did not affect CD4+ regulatory T cells ability
to suppress effector T cells in vitro, while MS patients CD4+ regulatory T cells
were unable to suppress T cell activation in vitro (2004). This demonstrates that
the ability of the regulatory T cells to suppress is altered in MS patients and that
an active immune response in vivo does not affect the in vitro results.
In EAE, the regulatory T cells were not observed to expand in the CNS,
but the regulatory T cells that were able to enter the CNS produced IL-10 in
response to stimulation with MOG35-55 (Korn, et al., 2007). Regulatory T cells
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collected from mice immunized with MOG35-55 can suppress specific
proliferation better than naïve cells, though both are equally able to suppress
non-specific CD3 stimulated cells (Korn, et al., 2007). Effector T cells from the
CNS were unable to be suppressed by regulatory T cells from the CNS, which
appeared to be due to the combination of high IL-6 and TNF-α levels found in
culture supernatants (Korn, et al., 2007). This may indicate that it is not just the
activation of the immune system that is stopping the suppression of the effector T
cells, but a problem with the CD4+ regulatory T cells ability to respond to the
immune response.
CD8+ regulatory T cells do not appear to be dysfunctional in MS, but are
not present in normal numbers compared to healthy controls during relapse
(Filaci, Fenoglio, & Indiver, 2011; Fletcher, Lalor, Sweeney, Tubridy, &Mills,
2010; Correale & Villa, 2008). This is especially true in the CNS of MS patients
(Correale & Villa, 2008). Correale and Villa found that the cloning frequency of
CD8+ regulatory T cells was not altered in MS patients (2010). CD8+ regulatory
T cells that are also Foxp3+ are able to reduce dendritic cells ability to present
myelin antigens to effector T cells through the downregulation of costimulatory
molecules in vitro (Correale & Villa, 2010). Cunnusamy et al. found that
suppression of CD4+ effector T cells by CD8+ regulatory T cells was decreased
in transwell culture compared to co-cultures with cells from MS patients (2014).
This demonstrated that some of the suppressive ability of CD8+ regulatory T
cells is through cell to cell contact but they also have some suppressive ability
through cytokine production. CD8+ regulatory T cells in MS are reduced in
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numbers but do not lose their ability to suppress, indicating that it may be that
CD8+ regulatory T cells are not able to enter the CNS effectively or their
numbers are not high enough to suppress the effector T cell response (Correale
& Villa, 2008).
Type 2 helper T cells

Th2 cells, like regulatory T cells, are anti-inflammatory cells in MS. Th2
cells are normally part of the humoral immune response and are implicated in
allergies. Th2 cells produce IL-10, IL-4, IL13 and IL-5, which suppress the
differentiation of Th1 cells and direct the differentiation of B cells and isotype
switching in antibodies (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira,
Chamorro, & Diez-Tejedor, 2012; Celik, et al., 2014; Levings, et al., 2001).Th2
cell differentiation is blocked by TGF-β (Travis & Sheppard, 2014). In in vitro
experiments, neurons incubated with Th2 cells were protected from damage
caused by a Th1 response (Yong, Giuliani, Xue, Bar-Or, & Metz, 2007). This is
hypothesized to be through the production of cytokines such as IL-10 (Yong,
Giuliani, Xue, Bar-Or, & Metz, 2007).
Th2 cells do not have a role in the progression of MS but Th2 cytokines
are up regulated during a relapse along with Th1 cytokines in RRMS patients (de
Andrés, et al., 2004). The cytokines produced by Th2 cells inhibit the
differentiation of Th1 cells. There has been research to determine how to shift the
T cell response toward Th2 cells and away from Th1 and Th17 response,
through the modulation of the immune response (Smolders, et al., 2009; OrejaGuevara, Ramos-Cejudo, Stark Aroeira, Chamorro, & Diez-Tejedor, 2012). This
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is how many of the treatments for MS currently work though this is not enough to
stop disease progression.
Research on treatments for MS that push the immune response toward to
a Th2 response are under development. It has been observed that vitamin D can
promote Th2 cell differentiation and increase Th2 cytokine levels in MS
(Smolders, et al., 2009; Sloka, Silva, Wang, & Yong, 2011). Vitamin D deficiency
has also been implicated as one of the environmental factors associated with the
development of MS, as many MS patients are vitamin D deficient (BerlangaTaylor, Disanto, Edbers, & Ramagopalan, 2011; Correale, Ysrraelit, & Gaitán,
2011). Vitamin D in its bioactive form, 1,25-dihydroxyvitamin D3, produces Th2
cells in culture of human cells through the induction of the STAT6 transcription
factor, which is important for Th2 cell differentiation (Sloka, Silva, Wang, & Yong,
2011).
Another treatment is peptide vaccine. Myelin protein peptides are injected
in high doses to induce a Th2 response (Pearson, van Ewijk, & McDevitt, 1997).
In the EAE model, it has been found that injections of high doses of peptide with
low T cell binding affinity can induce the apoptosis of Th1 cells and cause new T
helper cells to differentiate into Th2 cells (Pearson, van Ewijk, & McDevitt, 1997;
Katsara, et al., 2009). More recently, an analog of MBP, glatiramer acetate (GA),
has been used to treat MS. GA induces Th2 cytokines and reduces Th1
cytokines in MS patients (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira,
Chamorro, & Diez-Tejedor, 2012; Chen, et al., 2001). These patients also had a
reduced number of relapses and a reduction in the number of lesions seen on
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MRI scans (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira, Chamorro, & DiezTejedor, 2012). The exact mechanism of GA is still under investigation.
B cells in MS/EAE

The role of B cells in the pathogenesis of MS has been controversial.
Scientists agree that B cells play a role in the pathogenesis but what that role is,
is still under debate. This is due to inconsistent results observed between studies
because of differences between animal models and methods used (Lyons J.-A. ,
Ramsbottom, Mikesell, & Cross, 2008; Liu, Muili, Agashe, & Lyons, 2012; Lyons,
San, Happ, & Cross, 1999; Wilson, 2012; Abdul-Majid, et al., 2002; Urich,
Gutcher, Prinz, & Becher, 2006; Cross, Trotter, & Lyons, 2001; Dittel, Urbania, &
Janeway, 2000; Hjelmström, Penzotti, Henne, & Lybrand, 1998; Wolf, Dittel,
Hardardottir, & Janeway, 1996). There are several possible roles for B cells in
MS including: antigen presentation, production of proinflammatory cytokines,
secretion of antibodies, and regulation of the immune response.
B cells as APCs

Activated B cells are considered professional antigen presenting cells
(APC). B cells are potent APCs to T cells specific to the same antigen as the B
cell. For a B cell to present antigen, it must first bind antigen via the B cell
receptor (BCR). The antigen is broken down through antigen processing,
followed by presentation on the major histocompatibility complex (MHC) class II
molecule. The MHC/antigen complex interacting with T cell receptor (TCR) must
come together with the interaction of the B7 costimulatory molecule on the APC
with CD28 expression by the T cell. This leads to T cell activation and cytokine
production. Which cytokines are produced is dependent on the APC and the

13

environment in which T cell activation is occurring, leading to the generation of
either a pro- or anti-inflammatory response (Nakae, Iwakura, Suto, & Galli, 2007).
Other antigen presenting cells like dendritic cells can present antigen
taken up non-specifically (i.e. pinocytosis, phagocytosis), while B cells need to
bind antigen specifically by the BCR to efficiently present antigen (Chesnut &
Grey, 1981). B cells can perform pinocytosis and bind antibody via the Fcɣreceptor but these are not presented efficiently to T cells (Chesnut & Grey,
1981). This means that B cells only efficiently present antigen that they bind via
the BCR and T cells activated by B cells can only be presented epitopes in the
MHC molecule from the antigen bound by cross-linking on the BCR before
processing (Grey, Colon, & Chesnut, 1982). Once the BCR bound antigen is
taken in to the cell the antigen is transported to the early endosome compartment
and then quickly transported to the late endosome compartment where MHC
class II molecules are assembled (Cheng, Steele, Gu, Song, & Pierce, 1999).
There is evidence that interactions with B cells are needed for T cells to
become activated and enter the CNS (Ireland & Monson, 2011; Harp, LovettRacke, Racke, Frohman, & Monson, 2008). Furthermore, Duddy et al. (2007)
found that the maturity of the B cell may affect the cytokines produced in
response to activation, creating either a pro- or anti-inflammatory response. They
observed that naïve and memory B cells produced different cytokines on
activation and that these cytokines differed depending on if B cell activation was
antigen specific or by bystander mechanisms (Duddy, et al., 2007). This
observation, along with the success of the B cell depletion therapy for some MS
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patients (Harp, Lovett-Racke, Racke, Frohman, & Monson, 2008; Morris &
Yiannikas, 2012; Naismuth, et al., 2010), has led to the belief that T cell-B cell
interactions are an important part of disease progression in MS. Harp et al.
(2010) found that B cells from some RRMS patients could induce T cell
proliferation and IFN-ɣ production when stimulated with MBP and/or MOG, this
was not true for B cells from Healthy controls. They also demonstrated both
memory B cells and naïve B cells could induce T cells proliferation in response to
MOG, but MBP could only induce proliferation when presented by memory B
cells (Harp, et al., 2010). The effectiveness of B cells as APCs to T cells may be
a reason that B cell deletion therapy has been an effective treatment for some
MS patients (Ireland & Monson, 2011).
There are several things that can effect which antigens are presented to T
cells including the amino acid sequence of the antigen, the presence of antibody
bound to the antigen at the time of internalization, and regulating proteins in the
MHC assembly compartment (Alfonso, et al., 2003). In other antigen presenting
cells DM, a regulatory protein for MHC assembly which favors epitopes that
stably bind to MHC, is found as free heterodimers, while in B cells DM is closely
associated with DO, another MHC associated heterodimer protein found only in
B cells and some subsets of dendritic cells (Alfonso, et al., 2003; Kropshofer,
Hämmerling, & Vogt, 1999). This association means that antigen loading,
mediated by DM-DO, can only occur in a more acidic environment compared to
that of DM alone (Roucard, et al., 2001). DO is upregulated after BCR mediated
antigen up take and alters the presentation of some epitopes by either
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suppressing or promoting them though the acidic environment of the
endoplasmic reticulum, where MHC is assembled (Alfonso, et al., 2003; Roucard,
et al., 2001).
Another factor that can alter epitope presentation is the presence of
antibody bound to the antigen at the time of internalization (Simitsek, Campbell,
Lanzavecchia, Fairweather, & Watts, 1995). Like the binding of DO, the binding
of soluble antibody to antigen can suppress or promote selection of epitopes
(Simitsek, Campbell, Lanzavecchia, Fairweather, & Watts, 1995). The antibody
to antigen ratio determines if the T cells response to the antigen is promoted or
suppressed (Manca, Fenoglio, Pira, Kunkl, & Celada, 1991). This has been
observed in all antigen presenting cells (Manca, Fenoglio, Pira, Kunkl, & Celada,
1991; Watts & Lanzavecchi, 1993).
Cytokine production by B cells

B cells can produce several different proinflammatory cytokines including
IL-6, IFN-ɣ, Lymphotoxin (LT)-α, and TNF-α (Barr, et al., 2012; Ireland & Monson,
2011; Christensen, et al., 2012; Serafini, Rosicarelli, Magliozzi, Stigliano, &
Aloisi, 2004). Barr et al. demonstrated that B cell produce 86% of IL-6 in
secondary lymphoid tissue in EAE and another study found that neutralization of
IL-6 reduced disease in EAE (Erta, Quintana, & Hidalgo, 2012). IL-6 is a
proinflammatory cytokine important for the differentiation of Th17 cells and
plasma cells (Erta, Quintana, & Hidalgo, 2012). IFN-ɣ is also produced by B cells
which pushes the immune response toward a Th1 response (Ireland & Monson,
2011).
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Another cytokine produced by activated B cells is LT-α, which is important
for the formation of memory B cells, and along with TNF-α is associated with the
formation of ectopic follicles in the CNS (Ireland & Monson, 2011; Christensen, et
al., 2012; Serafini, Rosicarelli, Magliozzi, Stigliano, & Aloisi, 2004). Ectopic
follicles have been observed post mortem in MS patients and in EAE, and are
made up of follicular dendritic cells and proliferating B cells (Serafini, Rosicarelli,
Magliozzi, Stigliano, & Aloisi, 2004). The formation of these ectopic follicles is
associated with an increase in production of pro-inflammatory cytokines.
The role of antibody in MS/EAE

B cells that differentiate into plasma cells produce antibodies, which can
affect disease through multiple mechanisms including, activation of the
complement cascade, Fc receptor binding, and epitope selection. Antibody
bound to a cell’s surface can initiate the complement cascade, which can lead to
phagocytosis of the cells by macrophages or the formation of the membrane
attack complex causing damage to the cell membrane (Piddlesden, Lassmann,
Zimprich, Morgan, & Linington, 1993). Phagocytosis can also occur through
binding of the Fc region of the antibody when antigen is bound (Dharmasaroja,
2003; Abdul-Majid, et al., 2002). Furthermore, antibody-dependent cell-mediated
cytotoxicity is mediated by the binding of the Fc region by macrophages or
natural killer cells, inducing the release of inflammatory molecules, which leads to
the lysis of the target cell (Dharmasaroja, 2003; Piddlesden, Lassmann,
Zimprich, Morgan, & Linington, 1993). All of these actions have been observed in
MS lesions (Breij, et al., 2006; Dharmasaroja, 2003).
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Antibody specific to myelin proteins has been observed postmortem in
lesions of MS patients, the cerebral spinal fluid (CSF), and serum, but these
antibodies have also been observed in the serum of healthy controls, indicating
that the presence of myelin antibodies does not indicate disease when it is only
present in the periphery (Lucchinetti, et al., 2000; Villar, et al., 2005; von
Büdingen, et al., 2004). The bands found in the CSF and not the serum is a sign
of inflammation and antibody production in the CNS (Weber, Hemmer, & Cepok,
2011). These antibodies are termed oligoclonal bands and are found in about
90% of MS patients (Compston & Coles, 2008). The presence of these bands
increases the likelihood that the patient will develop clinically definite MS, as
opposed to a clinically isolated episode (Miller, Chard, & Ciccarelli, 2012). Those
patients that do not develop oligoclonal bands are thought to have a more mild
disease course (Huttner, et al., 2009; Rojas, Patrucco, Tizio, & Cristiano, 2012).
The presence of more oligoclonal bands indicates a more severe disease course
(Weber, Hemmer, & Cepok, 2011; Miller, Chard, & Ciccarelli, 2012; Cross,
Trotter, & Lyons, 2001).The presence of oligoclonal bands is used as a
diagnostic tool to help determine if the patient has MS, but oligoclonal bands are
not specific to MS (Miller, Chard, & Ciccarelli, 2012). Oligoclonal bands can also
be found in patients with late stage Lyme disease and neurosyphilis (Pachner &
Steere, 1985; Vartdal, Vandvik, Michaelsen , Loe, & Norrby, 1982).
Epitope spreading is a process by which responses to new epitopes are
developed during an immune response. These new epitopes are not overlapping
with the original epitope and may or may not be on the same protein as the
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original epitope (Vanderlugt, et al., 1998). This can occur in both the T cell and
antibody repertoire. Epitope spreading could follow tissue damage, making new
epitopes available for binding, or though the processing of antigen allowing
different epitopes to be presented. Epitope spreading of antibodies to several
myelin proteins has been correlated with the rate of relapse in three different
models of EAE and is thought to proceed in an ordered progression (Lehmann,
Fursthuber, Miller, & Sercarz, 1992; Robinson, et al., 2003; Yin, et al., 2001; Yu,
Johnson, & Tuohy, 1996). In EAE and at least some MS patients, the original
immunodominate epitope losses its capacity to stimulate the immune response,
but new epitopes take the place of the original epitope progressing the
autoimmune response (Tuohy, Yu, Yin, Kawczak, & Kinkel, 1999). This could be
due to the damage in the CNS allowing APCs like B cells to bind new epitopes
and present them to T cells, leading to the activation of a new set of autoreactive
T cells (Bischof, et al., 2004). The T cells then in turn would activate new
autoreactive B cells (Bischof, et al., 2004).
Antibodies specific to conformational epitopes are known to cause
demyelination in animal models using the extracellular MOG sequence, while
antibodies to linear epitopes do not, which is hypothesized to be because they
cannot bind native MOG (Breithaupt, et al., 2008; von Büdingen, et al., 2004;
Brehm, Piddlesden, Gardinier, & Linington, 1999). In other models where MOG
peptide is used to induce EAE, antibodies to linear epitopes are found to be
pathogenic (von Büdingen, et al., 2004). Antibodies binding conformational
epitopes have also been found in MS patients, while antibodies to linear epitopes
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have been found in both MS patients and healthy controls (Breithaupt, et al.,
2008). Conformational epitopes are thought to come first, activating B cells. The
B cells activate T cells using linear epitopes, which then activate B cells reactive
to these linear epitopes.
Regulatory B cells

There is a subset of B cells that have properties similar to those seen in
regulatory T cells. In EAE, regulatory B cells produce IL-10 in response to toll-like
receptor (TLR) 2 and 4 signaling (Ray, Mann, Basu, & Dittel, 2011). TLRs are
proteins found on the membrane of cells and in cells that activate the immune
response though the binding of conserved structural motifs found in bacteria and
viruses. In EAE, regulatory B cells are required for recovery mediated by
regulatory T cells (Marín, et al., 2014). Regulatory B cells also regulate the
immune response through cell-to-cell interactions with T cell by binding of the B7
and CD80/CD86 proteins (Ray, Mann, Basu, & Dittel, 2011; Mauri, 2010). Unlike
regulatory T cells, regulatory B cells do not appear to be defective in MS patients
and when stimulated produced significantly more IL-10 than healthy controls
(Ray, Mann, Basu, & Dittel, 2011). Furthermore, there is also evidence that direct
regulatory B cell interaction with T cells though CD28 and B7 is required for
recovery in EAE (Ray, Mann, Basu, & Dittel, 2011; Mizoguchi, Mizoguchi, Preffer,
& Bhan, 2000). This interaction may cause the activation of regulatory T cells,
since the regulatory T cell response is delayed in EAE when B cells are removed
(Ray, Mann, Basu, & Dittel, 2011; Mann, Ray, Basu, Karp, & Dittel, 2012;
Matsushita, Horikawa, Iwata, & Tedder, 2010). Additionally, B cell depletion
before induction of EAE with MOG35-55 increases disease severity, while
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depletion after disease onset decreases disease severity (Yanaba, et al., 2008;
Matsushita, Yanaba, Bouaziz, Fujimoto, & Tedder, 2008). This indicates that
regulatory B cells are more important early on in EAE.

Previous Studies
Our Previous data demonstrated that B cell-deficient (B cell-/-) mice are
not susceptible to EAE induction using the whole rMOG protein, but WT mice are
susceptible rMOG induction. This indicates that B cells are required for EAE
induction using rMOG. But when B cell-/- mice were injected with the MOG35-55,
the encephalogenic epitope of the MOG protein, the mice developed EAE like the
WT mice (Lyons et al., 1999). We also found that disease could be reconstituted
Figure 1: Serum
antibody ELISA of
rMOG or MOG35-85
peptide immunized
mice. WT animals were
immunized with rMOG or
MOG35-55 peptide and
serum was collected. A
serum antibody ELISA
was performed to
determine the specific
antibody responses,
observed with each
antigen. The animals
immunized with rMOG
or MOG35-55
demonstrated a
response against
MOG21-40, but
antibodies were also
observed in the rMOG
immunized mice
against amino acids
46-85.
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in the B cell-/- through the transfer of B cells or serum from rMOG primed WT
mice (Lyons, Ramsbottom and Cross, 2002). Plasma ELISA of the rMOG
induced WT mice reveled antibodies to linear epitopes between aa46-85 that
were not observed in the MOG35-55 induction (Figure 1) (Lyons et al.,
unpublished data; Liu et a., 2012).
Next T cell epitopes were studied. The expected encephalitogenic aa3555 epitope was observed in the WT and B cell-/- mice primed with rMOG. In
addition, a novel epitope at aa61-85 was observed in B cell-/- but not WT mice
(Figure 2) (Lyons et al., unpublished data; Liu et al., 2012). When B cell-/- mice
were co-immunized with MOG35-55 and MOG61-85 epitopes, disease severity
was decreased when compared with a MOG35-55 induction. Similar results were
observed in WT mice, which led to the conclusion that MOG61-85 is a cryptic

Figure 2: B cell-/- mice, but not WT B6
mice, respond to MOG61-85, when
immunized with rMOG. WT and B cell-/- were
immunized with rMOG in CFA. T cells were
isolated via negative selection from draining
lymph nodes 10 days post immunization.
Proliferation to a panel of overlapping 2025mer peptides spanning the rMOG protein
was evaluated. Analysis exposed an
additional response to MOG61-85 by T
cells isolated from B cell -/- mice that was
not observed in WT mice.

epitope, which is protective against the development of EAE (Figure 3) (Lyons et
al., unpublished data; Liu et al., 2012). This amelioration was observed whether
the peptide immunizations occurred at the same or different locations (Figure 3)
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(Lyons et al., unpublished data). This was corroborated by EAE induction with
MOG35-85 peptide, containing both the protective and encephalogenic epitopes.
Immunization of B cell-/- or WT mice with this longer peptide resulted in reduced
disease severity and incidence compared to MOG35-55 induction (Figure 4)
(Lyons et al., 1999; Lyons et al., unpublished data). This indicates that B cell
products have a role in disease initiation and perhaps in regulating the selection
of the MOG61-85 epitope.

A.

B.

● MOG35-55 alone
○ MOG35-55 + MOG61-85
■ MOG61-85 alone

C.

D.

Figure 3: Coimmuization of B6 mice with MOG35-55 and MOG61-85 at different
sited (left side) or at same site (right side) ameliorates EAE. WT (A, B) or B cell-/- (C,
D) C57BL/6 mice were immunized with the encephalitogenic MOG35-55 alone (closed
circles) or with MOG61-85 (open circles), and the clinical course of EAE was followed.
EAE clinical course was significantly less severe in animals co-immunized with
both peptides compared to animals receiving MOG35-55 alone, regardless of strain
(WT vs. B cell-/-). Immunization with MOG61-85 alone (closed squares) failed to
induce clinical EAE.
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Figure 4: Immunization with MOG35-85 peptide results in a decreased disease
severity in WT and B cell -/- animals as compared to the animals immunized with
MOG35-55. Animals were immunized with the appropriate peptide and observed for a
period of 29 days post immunization for EAE induction and progression. This graph shows
the complied results of all three experiments. Reduced disease severity in WT and B
cell-/- mice demonstrated the protective nature of the longer peptide.

Hypothesis and Aims
Previous studies in the EAE model have demonstrated that B cells are
required when rMOG is used for induction but not with the MOG35-55 induction.
Later studies demonstrated B-and T- cell responses unique for specific epitopes
in WT and B cell -/- mice immunized with MOG35-55 and MOG61-85. In
particular, a cryptic epitope was identified in the 61-85 amino acid sequence
which reduced severity of disease in WT and B cell -/- mice.
This work was to determine the effects of serum in disease progression of
EAE induction with both MOG35-55 and MOG61-85 epitopes on the disease
progression and cellular response to primed serum or purified antibody from
primed serum. I hypothesized that antibody specific for linear epitopes of rMOG
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in primed serum alter the immune response toward a proinflammatory response.
I addressed this with the following aims.
Specific Aims:
1. Determine the effect of antigen primed serum on disease severity and
proliferation in response to antigen. Working Hypothesis: was that the
response to the cryptic MOG61-85 epitope is blocked by the presence of
serum primed with the MOG35-55 and MOG61-85.
2. Determine the effect of purified antibody on disease severity and
proliferation in response to antigen. Working Hypothesis: was that the
response to the cryptic epitope MOG61-85 will be blocked by the
presence of purified antibody primed with rMOG.
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Chapter II: Materials and Methods
Mice
Specific pathogen free, female, WT C57bl/B6 mice and B cell-/- on a B6
background that were 6-8 weeks old were used for these experiments. All mice
used were bred in-house from breeding pairs purchased from Jackson
Laboratories (Bar Harbor, ME). Animals were housed in an Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited
facility on the University of Wisconsin Milwaukee (UWM) campus according to
university and National Institutes of Health (NIH) guidelines. All protocols used
were approved by the Institutional Animal Care and Use Committee.

Antigens
The MOG35-55 (MEVGWYRSPFSRVVHLYRNGK), and MOG61-85
(QAPEYRGRTELLKDAIGEGKVTLRI) peptides were obtained from GenScript
(Piscataway, NJ). These peptides were commercially synthesized and then
purified by High Performance Liquid Chromatography (HPLC). A 120 amino acid
sequence that makes up the extra cellular domain of human MOG, rMOG, was
isolated from culture supernatants of High-5 insect cells infected with a
recombinant baculovirus expressing the rMOG protein (Devaux, Enderlin,
Wallner, & Smilek, 1997).

Immunizations
Mice were immunized with 100 µg of rMOG or 50 µg of MOG35-55 and
MOG61-85 each emulsified in incomplete Freund’s adjuvant (IFA, MP
Biochemicals, Solon, OH) with 300 µg Mycobacterium tuberculosis strain H37RA
(TB, Difco Laboratories, Detroit, MI). Emulsions were prepared using Omni
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Homogenizer mechanical mixer and were injected subcutaneously at 4 sites,
near each limb. 300 ng of pertussis toxin (PT) (List Biological labs, Inc.,
Campbel, CA) in Phosphate Buffered saline (PBS-200mg/L, KCl-200mg/ml,
KH2PO4-8000 mg/L, NaOH-1150 mg/ml Na2HPO4) was also injected
intraperitoneally at the time of immunization and 72 hours post immunization.
Mice were injected with 100 µL of heat inactivated serum, from rabbits
immunized with MOG35-55 or MOG61-85 in a 1:100 dilution in normal mouse
serum, or serum from rabbits before immunization, preimmune serum, at the time
of immunization and three days following immunization. The serum was heat
inactivated by incubating serum at 55C overnight, this was done for all rabbit
serum used. This was done to inactivate complement present in the serum
samples, which could harm the mice if the complement was still active at the time
of injection. Purified antibody injections followed the same injection schedule as
the serum. The antibody was injected as a 1:100 dilution in PBS.

EAE grading
Mice were graded for the signs of clinical disease starting at 10 days post
immunization. The mice are graded on a scale from 0-5. Mice receiving a score
of 0 are free of clinical signs of disease; a score of 1 reflects a loss of muscle
tone in the tail (tail fails to “helicopter” when picked up); a score of 2 indicates
mice are unable to right themselves when placed on their backs; a score of 3
signifies paralysis or weakness in one hind limb; a score of 4 represents the
paralysis of both hind limbs; a score of 5 indicates the mice are dead or
moribund. Mice observed for clinical disease were graded for up to 30 days.
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Cell culture
For in vitro experiments, mice were euthanized 26-30 days post
immunization (dpi). Mice were anesthetized using ketamine (100 mg/ml), and
xylazine (300 mg/ml) mixture (1 ml ketamine + 0.15 ml xylazine + 4.6 ml water)
injected intramuscularly or inhalation of isoflourane. If serum was to be collected
then the mice were pinned down on a tray and cardiac puncture was performed
to collect serum and then cervical dislocation was performed. If no serum was
collected then after anesthetization cervical dislocation was performed before
mice were pinned to tray. The mice were then squirted with reagent grade
ethanol and an incision was made between the back legs of mouse then the skin
was separated from the peritoneal cavity. The incision was then extended up the
front of the mouse and each leg. The skin was then pinned open and squirted
with ethanol to remove any loose fur. The lymph nodes (LN) were removed using
tweezers and suspended in Hanks Balanced Salt Solution (HBSS). The
peritoneal cavity was then opened using scissors and the spleen (SPL) removed
using tweezers and suspended in HBSS. The LN and SPL were then
homogenized in sterile glass homogenizers and centrifuged to separate the cells
from the debris and fat. The SPL also had the red blood cells removed using
Lymphocyte Separation Media (LSM;MP Biomedical, Aurora, HO) or red blood
cell lysing buffer (Sigma, St Louis, MO). The cells were treated with tyrpan blue
(90 μl of 0.4% tyrpan blue solution + 10 μl of the cells) and counted using a
hemocytometer to determine viability and concentration of cells. Cell
concentration was determined using the following formula:

28

(No. of cells counted) (Dilution factor) (104)/ No. of squares counted = cells/mL
Cells were cultured in complete RPMI 1640 [penicillin (100 U/mL)/streptomycin
(100 µg/mL), L-glutamate (2 mM), sodium pyruvate (0.1 mM), 2-mecarptoethanol
(50 mM)] with 10% Fetal bovine serum (FBS) added. The cells were also
cultured with the appropriate antigen (MOG35-55, MOG61-85) at a concentration
of 20µg/mL, or Con A at 10µg/mL at a cell density of 2.5x10 6 cells/mL. A fourth
group was set up with no antigen present as a control. Cells were cultured up to
four days at 37˚ C with 10% CO2.

Serum collection
Mice were sedated using either isoflourane or a cocktail of molecular grade
water, ketamine, and zylazine. The mice were then pinned at each limb on a
dissection tray. A cardiac puncture was performed to remove to blood to tubes
containing 10µL of EDTA. The blood was kept on ice until all samples were
collected. The blood was centrifugated for 3 min 30 seconds at 2500rpm. The
serum was pipetted off into new tubes, pooled, aloquoted to 100µL per tube and
frozen at -80C until used.

Purification of IgG Antibody
IgG antibody was purified from mouse serum primed with rMOG. The purification
was done using magnetic bead purification (generous gift of Dr. Susan
Frackman, Promega, Madison, WI). Briefly, the beads were added to the tubes
and placed in magnet allowing the storage solution to be removed. The beads
were washed using the bind/wash buffer (25mM sodium acetate, pH 6). The
beads were mixed and then replaced in the magnet and the bind/wash buffer
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removed. Then 50µL of sample was added to 50µL of bind/wash buffer. This was
added to the beads and mixed continually for 30 minutes. The tube was then
placed back in the magnet and the supernatant removed and saved, this is the
serum in bind/wash buffer minus the IgG. The beads are washed three times in
the bind/wash buffer. 50µL of Elution buffer (100mM glycine-HCl, pH 2.7) was
added to the beads and mixed continually for 5 minutes. The beads were placed
in the magnet and the elutant was removed to a new tube and 10µL of the
neutralization buffer (2M Tris buffer, pH7.5). The elution was repeated. The titer
and purity of the elutant was determined using a serum antibody ELISA.

Antigen Presenting Cell Preparation
APCs were obtained from the spleen (SPL) of naïve WT mice. The SPL were
collected and prepped for culture as stated above with no antigen. Cells were
spun (500g 10min) and resuspended to a concentration of 8.1x106 cells/mL.
Then 100µL of mitomycin C (MP Biomedical, Aurora, OH) was added to the cells.
The cells were incubated in a water bath at 37C for 20 minutes, protected from
light. Cells were washed 3 times in HBSS with 5% FBS. Cells were cultured in
complete RPMI with 10% FBS at the concentration of 8.1x106 cells/mL in a 96
well plate, 100µL per well and were incubated at 37C with 10% CO 2 for 1 hour.
The cultures were mixed and the media removed and discarded. 100µL of
complete RPMI with 10% FBS was added to the wells. The APCs will adhere to
the wells so that the non-APCs were removed with the media after the wells were
mixed.
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T cell purification
T cells were purified using magnetic beads (STEMCELL, Vancouver, BC ).
Lymph nodes (LN) from immunized mice were prepped as stated above. The
cells were spun (500g, 10min) and resuspended at a concentration of
1x108cells/mL in 1mL HBSS with 2% FBS. 50µL of normal mouse serum was
added to the cells. Then 50µL of EasySepTM mouse CD4+ T cell isolation cocktail
was added and mixed well. This was incubated at room temperature for 10
minutes. While cells incubated EasySepTM streptavidin RapidSpheresTM for 30
seconds. Then 75µL of the RapidSpheresTM was added to the cells and mixed
well. This was incubated for 2.5 minutes at room temperature. The total volume
was brought up to 2mL by adding HBSS with 2% FBS and mixed well. The cells
were then placed in the magnet for 2.5 minutes. The tube was then picked up in
the magnet and the supernatant containing the purified T cells was poured into a
new tube. The cells were recounted using the same method as before. The T cell
purity was checked using flow cytometry using CD4, CD8 and CD19 as markers.
The percent purity was determined using Flow Jo software. The purified T cells
were then plated with the naïve APCs at a concentration of 2.5x10 6cells/mL with
either no antigen; Con A (10µg/mL); MOG35-55 (10µg/mL); or MOG61-85
(10µg/mL). All of these were plated for 48 and 72 hour readings with the CCK-8
protocol along with a set of the cells with a 1:100 dilution of purified IgG antibody
read at 72 hours.

Proliferation
Cells were obtained from LN and SPL were suspend in RPMI+10% FBS in tubes
to bring the cell starting concentration to 2.5x106cells/mL. The antigens were
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added to the cells at the appropriate concentrations. The cells were then plated
in duplicate in a 96 well plate 100μL per well. Wells with just RPMI+10% FBS
were used as a control. CCK-8 stain (Mayflower,St Louis,MO)was added (10μL)
per well and incubated at 37˚ C with 10% CO2 for four hours. The optical density
was measured using a Synergy™ HT Multi-Mode Microplate Reader (450nm;
Biotek, Winooski, VT).The cells were cultured for 48, 72, or 96 hours. The
standard used to determine cell concentrations at the time the optical density
was read was read at 24 hours. The standard cells were cultured with no antigen
and diluted 5 times using a 1:2 dilution starting at 2.5x106cells/mL as the top of
the standard.

Serum Antibody ELISA
The specificity of the serum collected was determined using a peptide antibody
ELISA. Peptides spanning the length of the rMOG protein were used to verify the
antibody specificity of IgG and IgM was consistent between collections. 96 well
plates (Corning Costar 9018) were coated using rMOG as a positive control and
just the bicarbonate coating buffer (sodium carbonate, sodium bicarbonate,
sodium azide, in deionized water pH9.6) as a negative control. Each of the
peptides was diluted to 10µg/mL in the coating buffer. These were incubated
over night at 4C. The wells were washed four times in a solution of PBS and
0.05% Tween 20. Blocking buffer (1.5g of BSA in 50mL of PBS) was added. This
was incubated for 2 hours. The plate was washed four times. The serum was
then added to the wells in two dilutions, 1:100 and 1:400, for each peptide and
immunoglobulin. The serum was diluted in dilution buffer (0.05% PBT, 0.5%BSA
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in PBS). This was incubated for one hour before washing four times. The
secondary antibody specific to either murine IgG or murine IgM was diluted to
1:40,000 or 1:20,000, respectively, and added to the wells. This incubated for
one hour. The plate was then washed once more and TMB substrate solution
from BD bioscience. The plate was incubated for 15 minutes before the stop
solution (2.5N sulfuric acid) was added to the wells before reading on the
Synergy™ HT Multi-Mode Microplate Reader (450nm and 562nm; Biotek,
Winooski, VT).

Statistics
All statistics were run using the computer program prism graphpad. All pvalues were set to 0.05 for significance. Differences in disease severity were
determined by a two-tailed T-test of the area under the curve for all mice in each
group. Day of onset was day first clinical signs of disease were observed no
number was given if mouse never displayed signs of disease. Proliferation
experiments were tested for significance using two-way ANOVA.
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Chapter III: Results
WT and B cell-/- mice were coimmunized with MOG35-55 and MOG61-85.
The mice were given two PT injections, at the time of immunization and day two
post immunization. Preimmune or immune serum was injected on day of
immunization and for 3 days following. An ELISA was run on the rabbit serum to

Figure 6: WT and B cell -/- mice were coimmunized with MOG35-55 and MOG61-85,
with preimmune rabbit serum or serum isolated from rabbits immunized with the 2
MOG peptides. The error bars represent standard error of the mean. WT and B cell-/mice injected with immune serum had more severe disease compared to those receiving
pre-immune serum. The WT mice were euthanized early (17dpi) due to tail biting
behavior observed. The B cell-/- mice were followed for 34 dpi. These data demonstrate
that the immune serum had an effect on disease severity in the B cell-/- mice.

verify the specificity of the antibodies in the serum. The mice were followed for
clinical signs of disease. Both WT and B cell-/- mice injected with the immune
Figure 5: Mean disease severity over the course of
the disease course seen above in WT and B cell-/mice. There was no significant difference observed
between the preimmune and the immune groups for
either the WT (p=0.114) or the B cell-/- mice (p=0.054).
This may have been due to small group sizes in the B
cell-/- mice. In the mice that displayed signs of
disease in B cell-/- recipients of immune serum, the
disease severity was much higher than those that
received pre-immune serum.

serum showed more severe signs of disease compared to mice given the
preimmune serum in the B cell -/- groups but not enough of the preimmune B
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cell-/- mice became sick to run a t-test (figure 5). This may be due to the
introduction of primed antibody to the immune system allowing the adaptive
immune response to be activated earlier in the disease

Figure 7: To investigate the mechanism of protection in recipients of immune
serum, the experiment was repeated with B cell -/- and IL-10 -/- mice. Mice were
followed for 26 days. The error bars represent the standard error of the mean. The B
cell-/- mice receiving immune serum demonstrated more severe disease
compared to mice receiving pre-immune serum. However there was little
difference observed between the same to groups of IL10-/- groups.

course. The day of onset was not significant in the WT mice (p-value=0.99). This
may have been because the WT mice produce their own antibody response. The
B cell -/- mice in the immune group had severe disease, while the preimmune
group had only minimal disease severity and incidence. The disease mean
disease severity was higher in the immune groups compared to the preimmune
groups in both the WT (p-value=0.114) and the B cell -/- (p-value=0.054) (figure
6). Significance was not reached in either group but both tended toward
significance and the group size was small. Both groups of WT mice were
sacrificed 17 dpi due to tail biting observed in the immune serum group. Serum
antibody ELISAs were run on serum taken from the WT mice to determine if the
rabbit antibodies could still be found. I was able to observe the presence of rabbit
IgG in the serum of the WT mice in the immune group. B cell -/- mice were not
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sacrificed until 34 dpi serum, spleens, and lymph nodes were collected. The
Lymph nodes from the preimmune B cell -/- group were observed to be larger
than expected from B cell -/- mice.
IL-10 deficient (IL-10-/-) mice and B cell -/- mice were coimmunized with
MOG35-55 and MOG61-85 as previously described. These mice were also split
into immune and preimmune serum groups. These mice were followed for 26 dpi
for clinical signs of disease (Figure 7). The day of disease onset was significantly
different in the B cell -/- mice in the preimmune and immune groups (pvalue=0.0079) (Figure 4). No significant difference in the day of onset was
observed in the IL-10-/- mice (p-value=0.7919). The mean disease severity was
significantly higher in the B cell -/- immune mice compared to the preimmune
group (p-value=0.0159) (Figure 8). The IL-10-/- mice mean severity did not reach
significance comparing the immune and preimmune groups (p-value=0.0952).
Once again the Lymph nodes from the B cell -/- mice in the preimmune group
were observed to be larger than expected.

Figure 8: The Mean disease severity was determined using the area under the curve
on the disease course graphs. No significant difference was observed between the IL-10-/groups (p=0.0952), but there was a significant difference between the B cell -/- immune and
preimmune groups (p=0.0159). This was also true for the day of onset of disease (p=0.0079)
for the B cell -/- mice. These data demonstrate that injection of immune serum at the
time of immunization increases disease severity in B-/- mice but not in the IL-10-/mice, suggesting that IL10 may be important in the observed clinical effect.
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The Lymph nodes and spleens were homogenized and cultured for CCK-8
testing at 48, 72, and 96 hours, with no antigen, Con A, MOG35-55, MOG61-85,
or both MOG35-55 and MOG61-85 (Figure 9). The absorbance was measured to
determine the proliferation in response to the stimuli. Proliferation was observed
to all three MOG cultures but the proliferation was higher in the preimmune
group. The difference in proliferation did not reach significance possibly due to
the small number of mice in each group. This along with the observation of the
larger than normal lymph nodes in the preimmune group led to the conclusion
that MOG61-85 presentation leads to the trapping of T cells in the lymph nodes
stopping their migration to the CNS.

Figure 9: The immune response to MOG35-55 and MOG61-85 in mice receiving preimmune or immune serum at the time of immunization was investigated using the CCK8 proliferation assay. Lymph node (LN) cells were isolated from B cell-/- mice receiving preimmune or immune serum and cultured with the indicated peptides in vitro for 48, 72, or 96
hours. Con A was used as a control for cell viability. Increased proliferation was observed
by cells from mice receiving pre-immune serum 72 hours for the MOG35-55 and MOG6185 groups, and for the MOG35-55+61-85 the same between the immune and preimmune
but the preimmune group was higher at 72 and 96 hour but this did not reach
significance. This suggests that the immune serum may be directing the development of
the T cell response, thus affecting disease severity in the EAE model.

To investigate the response of T cells to MOG35-55 and 61-85 with naïve
APCs, SPLs were collected from naïve WT mice and treated with mitomycin C to
stop the cells from proliferating. To ensure the culture only contained APCs the
cells were incubated for an hour at culture conditions, then the cultures were
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mixed and the media removed. This allowed the APCs to adhere to the culture
plate so that only the T and B cells were removed with the media. The APCs
were then incubated over night at culture conditions in RPMIc with 10% FBS.
The next day LNs were collected from B cell -/- mice coimmunized given either
immune or preimmune serum. The LNs were prepped for culture and then T cells
were purified from the cell suspension. The T cells were checked for purity using
flow cytometry staining for CD8, CD4, and CD19. Purity was determined to be

Figure 10: Flow cytometry of purified T cell suspension. The cells were stained
with CD4, CD8, and CD19. The cells were gated for Lymphocytes and then for CD4
and CD8. CD19 was used as a negative control and no CD19 was used staining was
observed. The CD4+ T cell population was found to be over 97% pure in both the
cells from the immune and preimmune groups.

greater than 97% (figure 10). Purified T cells were cultured with the mitomycin C
treated APCs. These were cultured for 48 or 72 hours. At 24 hours some of the
cells were treated with purified IgG from rMOG primed mice which were read at
72 hours. The purified antibody was tested with an ELISA to determine purity.
The ELISA showed that only IgG was in the elutent and that this was enriched for
IgG. There was little IgM seen even in the serum after the IgG was purified from
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it, though some of the IgG remained behind. These cells were read with the
CCK-8 dye. I found a higher response in the preimmune group to MOG61-85 at
both the 48 and 72 hour time point (Figure11). There was very little if any
response to the MOG35-55 this may been due to the number of freeze thaws the
peptide underwent. This experiment demonstrated that there is a T cell specific

Figure 11: Proliferation response to MOG35-55 and MOG61-85 in purified T cells
from the LN in B cell -/- mice coimmunized given either immune or preimmune
serum was investigated using the CCK-8 assay. T cells were purified from the LN
of B cell -/- coimmunized receiving either immune or preimmune serum. The T cells
were cultured with naïve APCs treated with mitomycin C and the MOG peptide
indicated in the graph for 48 to 72 hours. Con A was used as a positive control for cell
viability. There was a greater response to MOG61-85 in the preimmune group.
This was expected as B cell -/- mice produce a T cell response to MOG61-85 in
vivo. The immune group had little response to MOG61-85 and it occurred earlier
than in the preimmune group. This demonstrated that The T cells are
proliferating in response to MOG61-85 in the preimmune group and that this
response is not due to antigen carried over by APCs.

response to MOG61-85 in the preimmune group that is lost with the addition of
the immune serum. The proliferation seen also shows that this response is not
due to the carryover of antigen in APCs from the in vivo response as the APCs
used were naïve and did not contribute to the proliferation observed due to the
treatment of mitomycin C. Some of the wells had purified IgG from rMOG primed
WT mice added to the wells at 24 hours; these were read at 72 hours. The IgG
was tested for purity using ELISA and this was also used to determine the titer of
the antibody (figure 12). The titer of the purified IgG was
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Figure 12: Serum antibody ELISAs of serum and purified antibody from rMOG
immunized WT mice. The top 2 graphs are the ELISAs run shortly after collection. The
bottom graphs are the show the titers of the serum sample and the eluted purified IgG
antibody. There was an overall decrease in detectable antibody in both isotypes most likely
because of the dilution that occurred during purification. The IgG was further reduced due to
the incomplete purification. This means that the purification resulted in antibody
enriched for IgG subclasses due to better binding by the magnetic beads.

determined to be about 1:500 while the IgM left in the sample was 1:1000 but the
IgM did not dilute out as expected. The purified IgG was free of IgM but the
serum sample still had IgG though much less than the purified IgG of the elutant.
This may mean that the purification beads bind some IgG subclasses better than
others making the purified IgG enriched with those subclasses. It is also
important to note that the antibody and serum was diluted 1:2 in the purification
process. There was also a reduction in the absorbance measured in both IgG
and IgM was reduced overall. This is most likely due to the purification process
and possibly the freezing and thawing of the samples. The addition of the
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antibody was expected to increase the response to the MOG35-55 while

Figure 13: Proliferation response of purified T cells from the LN of B cell -/- mice
coimmunized, and incubated with naïve APCs after 72 hours of culture. The groups
marked +IgG had purified polyclonal IgG added to make a 1:100 dilution at 24 hours. The
addition of the IgG produced an overall decrease in the proliferation across all
treatments. This may have been due to the IgG being polyclonal causing an IVIG
like effect on the cells.

decreasing the response to MOG61-85. This was not observed, instead there
was an overall decrease in the response observed in the wells treated with IgG
(Figure 12). This may have been because the IgG was polyclonal and not
specific for MOG peptides. The polyclonal IgG may be producing a regulatory
response, which may be similar to that of Intravenous immunoglobulin (IVIG).
IVIG produces a regulatory response and is used to treat many diseases
including autoimmune and inflammatory diseases. This means that to produce
the expected proinflammatory response the antibody may need to be purified
down to those antibodies specific to MOG61-85 and MOG35-55.
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To determine if the same response would be observed in vivo mice were
injected with IgG purified from the serum of WT mice immunized with rMOG. IgG
from naïve mice was used as a negative control using the same purification
method as the primed IgG. Rabbit serum was used in earlier experiments was
used as a positive control. The antibody and rabbit serum was diluted to a 1:100
solution in PBS, or normal mouse serum respectively and injected in the
coimmunized B cell -/- mice at the time of immunization and the following 3 days.
The mice were followed for clinical signs of disease (figure 14). The day of onset

Figure 14: Coimmunized B cell -/- injected with immune IgG, naïve IgG, or immune
serum and followed for clinical signs of disease. The left graph shows the clinical
course of disease for all 3 groups. The immune serum appears to have lost potency over
time. The mean disease severity was determined by the area under the curve. The mice in
both IgG groups showed clinical signs of disease but the mice given naïve IgG did not have
as severe disease and began to recover earlier (p-value=0.2143). The recovery of the
naïve IgG group may have been due to an IVIG effect. This demonstrates that
antibody is important in initiation and disease progression.

was not significant comparing the immune IgG and naïve IgG. The disease
severity trended toward significance between the 2 groups (p-value=0.2729). The
mice in the immune serum showed no signs of clinical disease this may be due
to a loss of potency of the serum because of the length of time since the serum
had been defrosted. Both the immune IgG and naïve IgG groups started to show
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signs of disease about the same time but naïve IgG group began to recover
faster than the immune IgG group. This may mean that antibody is important in
the initiation disease but specific antibody is important for progression of disease.
It is also possible that the naïve IgG produced an IVIG effect leading to the
recovery of the mice that did show clinical signs of disease.
Together this data demonstrates that in EAE the protective effects of
MOG61-85 produced in B cell -/- mice coimmunized with MOG35-55 and
MOG61-85 is blocked by the addition of B cell products in serum, specifically
antibody. Evidence here suggests that IgG, possibly a specific subclass of IgG, is
altering the T cell response in B cell -/- mice most likely by affecting the
processing and presentation of MOG protein causing the MOG61-85 epitope to
be suppressed in WT mice. I also found evidence of how MOG61-85 may be
stopping the pro-inflammatory response. LN in the B cell-/- mice given the
preimmune serum were larger than that of the mice injected with immune serum,
which indicates that MOG61-85 may act by sequestering the T cell in the LN.
This supports other work in this lab suggesting that MOG61-85 induces the
production of TGF-β, which can alter immune cells ability to migrate (Wright, et
al., 2003).
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Chapter IV: Discussion and Conclusion
Discussion
This lab previously found that when EAE is induced with rMOG, B-/- mice do not

show clinical signs of disease, while disease severity increased to be similar to
that of the WT mice when immunized with MOG35-55 alone. This demonstrated
that B cells are required for rMOG induction of EAE in this model. Another
observation in rMOG induction was that B-/- mice produce T cells specific to
MOG61-85, which are not found in WT mice immunized with rMOG. WT mice
were found to produce antibodies to the MOG61-85 epitope. This lab has also
shown that mice coimmunized with the encephalogenic epitope, MOG35-55, and
the protective MOG61-85 epitope have reduced clinical disease in WT and B-/mice. When I immunized mice with both peptides and injected primed rabbit
serum, disease severity increased. This further indicated that the change in
clinical disease is caused by products produced by the B cells present in the
serum. The most likely candidate for this product is antibody. This also
demonstrated that it is most likely a response to MOG61-85 that is causing the
change in EAE severity because the severity of disease increased when serum
was added that was primed to MOG35-55 and MOG61-85 but not serum from
naïve rabbits indicating that antibody to other peptides was not involved in this
response.
It is accepted that antibodies to conformational epitopes of myelin proteins
contribute to demyelination in MS and in some models of EAE (Lucchinetti, et al.,
2000; Villar, et al., 2005; von Büdingen, et al., 2004; Piddlesden, Lassmann,
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Zimprich, Morgan, & Linington, 1993; Dharmasaroja, 2003). Our analysis
demonstrated antibodies specific for linear epitopes in WT mice immunized with
rMOG also play a role. The presence of these antibodies was consistent between
serum samples over several different experiments, and were consistently
demonstrated to be predominantly of the IgG subclass. This was also true of the
slight difference observed in the binding of the IgG and IgM in the peptides
covering the MOG35-55 epitope. The IgM bound MOG21-40 and the IgG bound
MOG21-45. This could just be an alteration in the binding between isotypes but
this may be important for how the antibodies affect disease in EAE. In fact the
only time these results significantly differed was when the serum sample was
from mice only 11dpi. In this case the antibodies spanning peptides covering
amino acids 46-85 were IgM antibodies instead of the IgG previously seen. This
indicates that isotype switching occurs early on in disease progression around
when the first signs of clinical disease can be observed. This important to note
since this occurs early on in the progression the class switching may be
important for how antibody is affecting the presentation of MOG61-85. This has
been observed in experiments investigating the processing and presentation of
tetanus toxoid and hen egg lysozyme are used as antigen (Simitsek, Campbell,
Lanzavecchia, Fairweather, & Watts, 1995; Amigorena, et al., 1998). This will
require a careful study of the time-course of the development of the antibody
response with rMOG immunization. Another possible study would be to
determine if the MOG35-55 and MOG61-85 antibodies work together or
independently in disease.

45

When clinical disease was observed in WT mice, mice in the immune
group had more severe disease than that of the preimmune group. While this did
not reach significance it demonstrates a trend that may have continued to reach
significance, if the biting behavior had not occurred or if repeated as it represents
a trend that was also observed in the B-/- mice. In the B-/- mice the disease
severity did reach significance when repeated. The B-/- mice also show a
significant difference in the day of onset of clinical disease not observed in the
WT mice. This may be due to the lack of B cells and therefore antibody in the B-/mice. The antibody response in WT mice develops quickly so that the addition of
immune antibody does not affect disease onset just the severity of disease.
While in B cell-/- mice the addition of antibody that would not normally be present
cause clinical signs to develop earlier and increases severity of disease. The
rabbit antibody was observed to still be present in the serum of WT mice 17 dpi.
Further tests should be run to determine if this is also true in the B-/- mice.
I also looked at the proliferation in cell culture to determine the effects of
serum on the response of immune cells to MOG35-55 and MOG61-85. While
these results were not significant, a trend can be observed in the responses in
the immune and preimmune groups, which may become significant when
repeated. There was more proliferation in the preimmune group compared to the
immune group in both the MOG35-55 and MOG61-85 conditions at 72 hours but
by 96 hours the numbers had dropped back down to similar to the levels seen in
the immune group. This could indicate that the activated cells are sequestered in
the LN in the preimmune group, while in the immune group these cells have
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migrated to the CNS by the time the LN were collected. Another indication of this
was the observation that the LNs in the preimmune group were larger than those
in the immune group. This could be determined by comparing the lymphocytes in
the CNS and the periphery. This would make sense, since previously this lab
found that IL-10 is not involved in the protection produced by the MOG61-85
epitope and the next cytokine candidate currently being investigated is TGF-β.
TGF-β is known to be able to alter cell migration in several organs including bone
marrow, gut, and endothelium (Wright, et al., 2003; Zhang & Bevan, 2013;
Godefroy, Guironnet, Jacquet, Schmitt, & Staquet, 2001).
Although there was no significant difference observed in the clinical
disease course in IL-10-/- mice when injected with immune or preimmune serum
at immunization, this could be due to the small number of mice in these groups
and may reach significance if repeated. One difference to note in the IL-10-/mice was that the preimmune group had more severe disease than that of the
immune group. This indicates that IL-10-/- is not a factor in the effect produced
by the MOG61-85, which is consistent with all the other data collected by this lab
that indicates that IL-10 is not important in the MOG61-85 response. Another test
that could help determine if IL-10 is important would be an IL-10 ELISA on cell
culture supernatants and previously when ELISAs were run on cell culture
supernatants only very low amounts if any IL-10 were present.
When the proliferation of T cells was measured from cultures with naïve
APCs, I found the preimmune group had a stronger response to MOG61-85 at
both the 48 and 72 hour time points than the immune group. There was only a
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small response to MOG61-85 in the immune group. The small response to
MOG61-85 observed in the immune group could be explained by results
previously demonstrated by this lab that when the peptides are injected in a
single emulsion there is a response produced to both peptides in both WT and B/- mice (Liu, Muili, Agashe, & Lyons, 2012). There was no response to MOG3555 in either the preimmune or immune group. This may have been due to the
high number of freeze thaws that the peptide had gone through. This could have
caused the peptide to denature losing the reactivity in culture.
At 72 hours culture there were also wells with purified IgG added to some
of the wells these were compared to the wells without IgG added. The wells with
the IgG added had a decreased response to both peptides and the positive
control Con A. This could be explained by the IgG producing a regulatory
response similar to that of intravenous immunoglobulin (IVIG), is a polyclonal
pool of all immunoglobulin subclasses. IVIG is used to treat autoimmune and
inflammatory diseases and is known to induce regulatory T cell expansion and
enhance their suppressive capabilities (Ballow, 2011; Maddur, et al., 2010). This
may explain the reduction in proliferation to all stimuli observed in the cultures
with IgG added. This may also mean that antibodies may need to be further
purified to exclude all but those specific to MOG35-55 and MOG61-85 to see the
expected results in cell culture.
To determine if this effect would be observed in vivo mice were
coimmunized and injected with purified IgG from rMOG primed serum or naïve
IgG from WT mice. The mice given the immune IgG showed more severe
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disease than the naïve IgG group. Furthermore, the naïve IgG group recovered
faster than the immune IgG group. This may have been due to the same IVIG
effect observed in the cell cultures. The disease course of the mice also indicated
that antibody is important for disease initiation but also for disease progression in
this model of EAE. The antibody used in this experiment was of the IgG isotype
but based on the results of the ELISA analysis is most likely has more of some
subclasses of IgG than others due to the incomplete purification of the serum
sample. According to the Promega protocol the magnetic beads bind most
strongly to the IgG1 and IgG2A subclasses but also bind IgG2B and IgG3. The
subclasses present in both the sample and the eluted antibody should be
determined to give a better indication of the mechanism of action of the IgG,
since different subclasses are known to promote or inhibit epitope selection
(Vidarsson, Dekkers, & Rispens, 2014). The role of IgM in the initiation of
disease should also be ruled out in future studies.

Conclusion
Together these studies indicate that IgG is altering the processing and
presentation of MOG protein in B6 mice. Alfonso et al. demonstrated that the
addition of specific immunoglobulin to cultures inhibited the presentation of
epitopes known to be presented in the absence of immunoglobulin (2003). I
hypothesize that this occurs when APCs take in antigen bound by antibodies
specific to MOG61-85 epitope through pinocytosis or Fc receptor binding. The
suppression of epitopes in other models has not been able to be blocked by any
available knock-out (Heyman, 2014). This gives credence to pinocytosis as the
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entry method of the antigen-antibody complex over the Fc receptor. Though it
does not rule out that more than one entry rout is used. Once the antigenantibody complex it is taken in to the APC the complex moves to the endocytic
compartment. Here the complex is exposed to a low pH environment. It is
possible that the bound antibody affects the breakdown of MOG protein into
epitopes in the endosome. Another possibility is that the antibody affects the
peptides, produced in the endosome, ability to bind to the MHC. I think the
alteration of peptide production is more likely since antibody is not stable in acidic
environments. The altered MOG61-85 peptide may be too short, too long or not
have side chains that allow it to create a stable binding with the MHC molecule.
So that when the epitope tries to bind to the MHC the regulator protein MHC-DM
removes MOG61-85 from the MHC because the binding is not stable enough.
Meaning that MOG61-85 is not presented to T cell only MOG35-55 is presented
leading to a proinflammatory response.
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Figure 15: Effect of antibody on epitope selection. The antibody-antigen complex
enter the cell and are broken down in the acidic environment of the endosome. The
presence of the antibody changes how the antigen breaks down in the endosome so that
the MOG61-85 epitope (teal) cannot be presented. The peptide may be shortened,
too long, or no long have the kinetic stability to bind the MHC (green). In any of
these cases the peptide is not presented.

51

Chapter V: References

Abdul-Majid, K.-B., Stefferl, A., Bourquin, C., Lassmann, H., Linington, C.,
Olsson, T., . . . Harris, A. (2002). Fc Receptors are Critical for
Autoimmune Inflammatory Damage to the Central Nervous System in
Experimental Autoimmune Encephalomyelitis. Scandinavian Journal of
Immunology, 55(1), 70-81.
Alfonso, C., Williams, G., Han, J.-O., Westberg, J. A., Winqvist, O., & Karlsson,
L. (2003). Analysis of H2-O Influence on Antigen Presentation by B Cells.
Journal of immunology, 171(5), 2331-2337.
Amigorena, S., Lankar, D., Briken, V., Gapin, L., Viguier, M., & Bonnerot, C.
(1998). Type II and III Receptors for Immunoglobulin G (IgG) Control the
Presentation of Different T Cell Epitopes from Single IgG-complexed
Antigens. Journal of Experimental Medicine, 187(4), 505-515.
Ballow, M. (2011). The IgG molecule as a biological immune response modifier:
Mechanisms of action of intravenous immune serum globulin in
autoimmune and inflammatory disorders. Journal of Allergy and clinical
immunology, 127(2), 315–323.
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., . . .
Gray, D. (2012). B Cell Depletion Therapy Ameliorates Autoimmune
Disease Through Ablation of IL-6–Producing B Cells. The Journal of
Experimental Medicine, 209(5), 1001-1010.
Berlanga-Taylor, A. J., Disanto, G., Ebers, G. C., & Ramagopalan, S. V. (2011).
Vitamin D–Gene Interactions in Multiple Sclerosis. Journal of the
Neurological Sciences, 311(1-2), 32-36.
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., . . . Kuchroo,
V. K. (2006). Reciprocal developmental pathways for the generation of
pathogenic effector TH17 and regulatory T cells. Nature, 441, 235-238.
Bischof, F., Bins, A., Dürr, M., Zevering, Y., Melms, A., & Kruisbeek, A. M.
(2004). A Structurally Available Encephalitogenic Epitope of Myelin
Oligodendrocyte Glycoprotein Specifically Induces a Diversified
Pathogenic Autoimmune Response. Journal of Immunology, 173(1), 600606.
Brehm, U., Piddlesden, S. J., Gardinier, M. V., & Linington, C. (1999). Epitope
specificity of demyelinating monoclonal autoantibodies directed against
the human myelin oligodendrocyte glycoprotein (MOG). Journal of
Neuroimmunology, 97(1-2), 9-15.

52

Breij, E. C., Heijnen, P., van der Goes, A., Teunissen, C. E., Polman, C. H., &
Dijkstra, C. D. (2006). Myelin flow cytometry assay detects enhanced
levels of antibodies to human whole myelin in a subpopulation of multiple
sclerosis patients. Journal of Neuroimmunology, 176(1-2), 106-114.
Breithaupt, C., Schäfer, B., Pellkofer, H., Huber, R., Linington, C., & Jacob, U.
(2008). Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific
Autoantibody Response Is Focused on One Dominant Conformational
Epitope Region in Rodents. Journal of immunology, 181(2), 1255-1263.
Celik, S. K., Öz, Z. S., Dursun, A., Unal, A., Emre, U., Cicek, S., & Keni, F. M.
(2014). Interleukin 18 gene polymorphism is a risk factor for multiple
sclerosis. Molecular Biology Reports, 41(published online), 1-6.
Chen, M., Gran, B., Costello, K., Johnson, K., Martin, R., & Dhib-jalbut, S. (2001).
Glatiramer acetate induces a Th2-biased response and crossreactivity
with myelin basic protein in patients with MS. Multiple Sclerosis, 7(4), 209219.
Cheng, P. C., Steele, C. R., Gu, L., Song, W., & Pierce, S. K. (1999). MHC Class
II Antigen Processing in B Cells: Accelerated Intracellular Targeting of
Antigens. Journal of Immunology, 162(12), 7171-7180.
Chesnut, R. W., & Grey, H. M. (1981). Studies on the Capacity of B Cells to
Serve as Antigen-Presenting Cells. Journal of immunology, 126(3), 10751079.
Christensen, J. R., Börnsen, L., Hesse, D., Krakauer, M., Soelberg Sørensen, P.,
Bach Søndergaard, H., & Sellebjerg, F. (2012). Cellular Sources of
Dysregulated Cytokines in Relapsing-Remitting Multiple Sclerosis. Journal
of Neuroinflammation, 9(1), 215.
Compston, A., & Coles, A. (2008). Multiple Sclerosis. Lancet, 372(9648), 150217.
Correale, J., & Villa, A. (2008). Isolation and characterization of CD8+ regulatory
T cells in multiple sclerosis. Journal of Neuroimmunology, 195(1-2), 121134.
Correale, J., & Villa, A. (2010). Role of CD8+ CD25+ Foxp3+ Regulatory T Cells
in Multiple Sclerosis. Annals of Neurology, 67(5), 625-638.
Correale, J., Ysrraelit, M., & Gaitán, M. (2011). Vitamin D-Mediated Immune
Regulation in Multiple Sclerosis. Journal of the Neurological Sciences,
311(1-2), 23-31.
Cross, A. H., & Waubant, E. (2011). MS and the B Cell Controversy. Biochimica
et Biophysica Acta-Molecular Basis of Disease, 1812(2), 231-238.

53

Cross, A. H., Trotter, J. L., & Lyons, J.-A. (2001). B cells and antibodies in CNS
demyelinating disease. Journal of Neuroimmunology, 112, 1-14.
Cunnusamy, K., Baughman, E. J., Franco, J., Ortega, S. B., Sinha, S.,
Chaudhary, P., . . . Karandikar, N. J. (2014). Disease exacerbation of
multiple sclerosis is characterized by loss of terminally differentiated
autoregulatory CD8+ T cells. Clinical Immunology, 152(1-2), 115-126.
de Andrés, C., Rodríguez-Sáinz, M., Muñoz-Fernández, M., López-Lazareno, N.,
Rodríguez-Mahou, M., Vicente, A., . . . Sánchez-Ramón, S. (2004). Shortterm sequential analysis of sex hormones and helper T cells type 1 (Th1)
and helper T cells type 2 (Th2) cytokines during and after multiple
sclerosis relapse. European cytokine network, 15(3), 197-202.
Dharmasaroja, P. (2003). Specificity of autoantibodies to epitopes of myelin
proteins in multiple sclerosis. Journal of Neurological Sciences, 1, 7-16.
Dittel, B. N., Urbania, T. H., & Janeway, C. A. (2000). Relapsing and Remitting
Experimental Autoimmune Encephalomyelitis in B Cell Deficient Mice.
Journal of Autoimmunity, 14, 311-318.
Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., . . . BarOr, A. (2007). Distinct Effector Cytokine Profiles of Memory and Naive
Human B Cell Subsets and Implication in Multiple Sclerosis. Joural of
Immunology, 178(10), 6092-6099.
Erta, M., Quintana, A., & Hidalgo, J. (2012). Interleukin-6, a Major Cytokine in the
Central Nervous System. International Journal of Biological Sciences,
8(9), 1254–1266.
Fallarino, F., Grohmann, U., Hwang, K., Orabona, C., Vacca, C., Bianchi, R., . . .
Puccetti, P. (2003). Modulation of tryptophan catabolism by regulatory T
cells. Nature immunology, 4(12), 1206-1212.
Filaci, G., Fenoglio, D., & Indiver, F. (2011). CD8+ T regulatory/supressor cells
and their relationships with autoreactivity and autoimmunity.
Autoimmunity, 44(1), 51-57.
Fletcher, J. M., & Mills, K. H. (2012). Immunology of MS. In G. Atkins, S. Amor, J.
Fletcher, & K. Mills, The Biology of Multiple Sclerosis (pp. 66-68).
Cambridge: Cambridge University Press.
Fletcher, J., Lalor, S., Sweeney, C., Tubridy, N., & Mills, K. (2010). T Cells in
Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
Clinical and Experimental Immunology, 162(1), 1-11.
Friese, M. A., & Fugger, L. (2009). Pathogenic CD8+ T Cells in Multiple
Sclerosis. Annals of Neurology, 66(2), 132-141.

54

Godefroy, S., Guironnet, G., Jacquet, C., Schmitt, D., & Staquet, M. (2001). A
combination of MIP-3alpha and TGF-beta1 is required for the attraction of
human Langerhans precursor cells through a dermal-epidermal barrier.
European Journal of Cell Biology, 80(5), 335-340.
Gourraud, P.-A., Harbo, H. F., Hauser, S. L., & Baranzini, S. E. (2012). The
Genetics of Multiple Sclerosis: an Up-To-Date Review. Immunological
Reviews, 1, 87-103.
Goverman, J. M. (2011). Immune Tolerance in Multiple Sclerosis. Immunology
Reviews, 241(1), 228-240.
Goverman, J., Woods, A., Larson, L., Weiner, L. P., Hood, L., & Zaller, M. D.
(1993). Transgenic mice that express a myelin basic protei-specific T cell
recepter develop spontaneous autoimmunity. Cell, 72(4), 551-560.
Greer, J. M., Cameron, K. D., McCombe, P. A., Good, M. F., & Pender, M. P.
(1997). Increased immunoreactivity to two overlapping peptides of myelin
proteolipid protein in multiple sclerosis. Brain, 120(Pt 8), 1447-1460.
Grey, H. M., Colon, S. M., & Chesnut, R. W. (1982). Requirements for the
processing of antigen by antigen-presenting B cells. II. Biochemical
comparison of the fate of antigen in B cell tumors and macrophages.
Journal of Immunology, 129(6), 2389-2395.
Harp, C. T., Ireland, S., Davis, L. S., Remington, G., Cassidy, B., Cravens, P. D.,
. . . Monson, N. L. (2010). Memory B cells from a subset of treatmentnaı¨ve relapsing-remitting multiple sclerosis patients elicit CD41 T-cell
proliferation and IFN-c production in response to myelin basic protein and
myelin oligodendrocyte glycoprotein. European Journal of Immunology,
40(10), 2942-2956.
Harp, C. T., Lovett-Racke, A. E., Racke, M. K., Frohman, E. M., & Monson, N. L.
(2008). Impact of myelin-specific antigen presenting B cells on T cell
activation in multiple sclerosis. Clinical Immunology, 128(3), 382-391.
Hedegaard, C. J., Krakauer, M., Bendtzen, K., Lund, H., Sellebjerg, F., &
Nielsen, C. H. (2008). T Helper Cell Type 1 (Th1), Th2 and Th17
Responses to Myelin Basic Protein and Disease Activity in Multiple
Sclerosis. Immunology, 125(2), 161-169.
Heyman, B. (2014). Antibodies as Natural Adjuvants. Current Topics in
Microbiology and Immunology: Fc Receptors, 382, 201-219.
Hjelmström, P., Penzotti, J. E., Henne, R. M., & Lybrand, T. P. (1998). A
Molecular Model of Myelin Oligodendrocyte Glycoprotein. Journal of
Neurochemistry, 71, 1742-1749.

55

Hu, D., Weiner, H. L., & Ritz, J. (2013). Identification of Cytolytic CD1612CD56+
Regulatory CD8 T Cells in Human Peripheral Blood. PloS one, 8(3),
e59545.
Huseby, E. S., Huseby, P. G., Shah, S., Rebecca, S., & Stadinski, B. D. (2012).
Pathogenic CD8T cells in multiple sclerosis and its experimental models.
Frontiers in immunology, 3(64), 1-9.
Huttner, H. B., Schellinger, P. D., Struffert, T., Richter, G., Engelhorn, T.,
Bassemir, T., . . . Doerfler, A. (2009). MRI Criteria in MS Patients with
Negative and Positive Oligoclonal Bands: Equal Fulfillment of Barkhof’s
Criteria but Different Lesion Patterns. Journal of Neurology, 256(7), 11211125.
Ireland, S., & Monson, N. (2011). Potential Impact of B Cells on T Cell Function
in Multiple Sclerosis. Multiple Sclerosis International, 2011, 1-9.
Jafari, N., & Hintzen, R. Q. (2011). The Association Between Cigarette Smoking
and Multiple Sclerosis. Journal of the Neurological Sciences, 311(1-2), 7885.
Katsara, M., Yuriev, E., Ramsland, P. A., Tselios, T., Deraos, G., Lourbopoulos,
A., . . . Apostolopoulos, V. (2009). Altered peptide ligands of myelin basic
protein (MBP87–99) conjugated to reduced mannan modulate immune
responses in mice. Immunology, 128(4), 521-533.
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., . . .
Iwakura, Y. (2006). IL-17 Plays an Important Role in the Development of
Experimental Autoimmune Encephalomyelitis. Journal of immunology,
177(1), 566-573.
Korn, T., Reddy, J., Gao, W., Bettelli, E., Awasthi, A., Petersen, T. R., . . .
Kuchroo, V. K. (2007). Myelin-specific regulatory T cells accumulate in the
CNS but fail to control autoimmune inflammation. Nature Medicine, 13(4),
423-431.
Kreymborg, K., Etzensperger, R., Dumoutier, L., Haak, S., Rebollo, A., Buch, T., .
. . Becher, B. (2007). IL-22 Is Expressed by Th17 Cells in an IL-23Dependent Fashion, but Not Required for the Development of
Autoimmune Encephalomyelitis. Journal of immunology, 179(12), 566573.
Kropshofer, H., Hämmerling, G. J., & Vogt, A. B. (1999). The impact ofthe nonclassical MHC proteins HLA-DM and HLA-DO on loading of MHC class II
molecules. Imunological Reviews, 172(1), 267-278.
Kursula, P. (2008). Structural properties of proteins specific to the myelin sheath.
Amino Acids, 34(2), 175-185.

56

Lafaille, J. J., Nagashima, K., Katsuki, M., & Tonegawa, S. (1994). High
incidence of spontaneous autoimmune encephalomyelitis in
immunodefiicent anti-myelin basic protein T cell receptor transgenic mice.
Cell, 78(3), 399-408.
Leary, S. M., & Thompson, A. J. (2005). Primary Progressive Multiple Sclerosis.
CNS Drugs, 19(5), 369-376.
Lehmann, P. V., Fursthuber, T., Miller, A., & Sercarz, E. E. (1992). Spreading of
T-cell autoimmunity to cryptic determinants of an autoantigen. Letters to
Nature, 358, 155-157.
Levings, M. K., Sangregorio, R., Galbiati, F., Squadrone, S., de Waal Malefyt, R.,
& Roncarolo, M.-G. (2001). IFN-a and IL-10 Induce the Differentiation of
Human Type 1 T Regulatory Cells. Journal of Immunology, 166(9), 55305539.
Liu, G., Muili, K. A., Agashe, V. V., & Lyons, J.-A. (2012). Unique B cell
responses in B cell-dependent and B cell-independent EAE.
Autoimmunity, 45(3), 199-209.
Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M., &
Lassmann, H. (2000). Heterogeneity of Multiple Sclerosis
Lesions:Iimplications for the Pathogenesis of Demyelination. Annals of
Neurology, 47(6), 707-717.
Lyons, J.-A., Ramsbottom, M. J., & Cross, A. H. (2002). Critical role of antigenspecific antibody in experimental autoimmune encephalomyelitis induced
by recombinant myelin oligodendrocyte glycoprotein. European Journal of
Immunology, 32(7), 1905-1913.
Lyons, J.-A., Ramsbottom, M. J., Mikesell, R. J., & Cross, A. H. (2008). B Cells
Limit Epitope Spreading and Reduce Severity of EAE Induced with PLP
Peptide in BALB/c Mice. Journal of Immunology, 31(2), 149–155.
Lyons, J.-A., San, M., Happ, M. P., & Cross, A. H. (1999). B cells are critical to
induction of experimental allergic encephalomyelitis by protein but not by a
short encephalitogenic peptide. European Journal of Immunology, 29,
3432-3439.
Maddur, M. S., Othy, S., Hegde, P., Vani, J., Lacroix-Desmazes, S., Bayry, J., &
Kaveri, S. V. (2010). Immunomodulation by Intravenous Immunoglobulin:
Role of Regulatory T Cells. Journal of Clinical immunology, 30(1S), 4-8.
Manca, F., Fenoglio, D., Pira, G. L., Kunkl, A., & Celada, F. (1991). Effect of
Antigen/Antibody Ratio on Macrophage Uptake, Processing, and
Presentation to T Cells of Antigen Complexed with Polyclonal Antibodies.
Journal of Experimental Medicine, 173(1), 37-48.

57

Mann, M. K., Ray, A., Basu, S., Karp, C. T., & Dittel, B. N. (2012). Pathogenic
and Regulatory Roles for B Cells in Experimental Autoimmune
Encephalomyelitis. Autoimmunity, 45(5), 388-399.
Marik, C., Felts, P., Bauer, J., Lassmann, H., & Smith, K. (2007). Lesion Genesis
in a Subset of Patients with Multiple Sclerosis: a Role for Innate Immunity.
Brain, 130(11), 2800-2815.
Marín, N., Mecha, M., Espejo, C., Mestre, L., Eixarch, H., Montalban, X., . . .
Villar, L. M. (2014). Regulatory lymphocytes are key factors in MHCindependent resistance to EAE. Journal of Immunology Research, 2014,
10.
Matsushita, T., Horikawa, M., Iwata, Y., & Tedder, T. F. (2010). Regulatory B
Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in
Controlling Experimental Autoimmune Encephalomyelitis Initiation and
Late-Phase Immunopathogenesis. Journal of Immunology, 185(4), 22402252.
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008).
Regulatory B cells inhibit EAE initiation in mice while other B cells promote
disease progression. The Journal of Clinical Investigation, 118(10), 3420–
3430.
Matusevicius, D., Kivisäkk, P., He, B., Kostulas, N., Özenci, V., Fredrikson, S., &
Link, H. (1999). Interleukin-17 mRNA expression in blood and CSF
mononuclear cells augmented in multiple sclerosis. Mutiple Sclerosis, 5,
101-104.
Mauri, C. (2010). Regulation of Immunity and Autoimmunity by B Cells. Current
Opinion in Immunology, 22(6), 761-767.
Meinl, E., Weber, F., Drexler, K., Morelle, C., Ott, M., Saruhan-Direskeneli, G., . .
. Giegerich, G. (1997). Myelin basic protein-specific T lymphocyte
repertoire in multiple sclerosis. Complexity of the response and
dominance of nested epitopes due to recruitment of multiple T cell clones.
The Journal of Clinical Invesigation, 92(6), 2633-2643.
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012). Clinically isolated syndromes.
Lancet Neurology, 11(2), 157-169.
Mizoguchi, E., Mizoguchi, A., Preffer, F. I., & Bhan, A. K. (2000). Regulatory role
of mature B cells in a murine model of inflammatory bowel disease.
International immunology, 12(5), 597-605.
Morris, K., & Yiannikas, C. (2012). Treatment Update in Multiple Sclerosis.
Current Allergy and Asthma Reports, 12(3), 246-254.

58

Naismuth, R., Piccio, L., Lyons, J., Lauber, J., Tutlam, N., Parks, B., . . . Cross,
A. (2010). Rituximab Add-On Therapy For Breakthrough Relapsing
Multiple Sclerosis: a 52-Week Phase II Trial. Journal of Neurology, 74(23),
1860-1867.
Nakae, S., Iwakura, Y., Suto, H., & Galli, S. J. (2007). Phenotypic differences
between Th1 and Th17 cells and negative regulation of Th1 cell
differentiation by IL-17. Journal of Leukocyte Biology, 81(5), 1258-1268.
Noonan, C. W., Williamson, D. M., Henry, J. P., Indian, R., Lynch, S. G.,
Neuberger, J. S., . . . Marrie, R. (2010). The Prevalence of Multiple
Sclerosis in 3 US Communities. Preventing Chronic Disease Public Health
Research, Practice, and Policy, 7(1), 1-8.
Oreja-Guevara, C., Ramos-Cejudo, J., Stark Aroeira, L., Chamorro, B., & DiezTejedor, E. (2012). TH1/TH2 Cytokine Profile in Relapsing-Remitting
Multiple Sclerosis Patients Treated with Glatiramer. BMC neurology,
12(1), 95.
Pachner, A. R., & Steere, A. C. (1985). The triad of neurologic manifestations of
Lyme disease: Meningitis, cranial neuritis, and radiculoneuritis. Neurology,
35(1), 47-53.
Pearson, C., van Ewijk, W., & McDevitt, H. (1997). Induction of apoptosis and T
helper 2 (Th2) responses correlates with peptide affinity for the major
histocompatibility complex in self-reactive T cell receptor transgenic mice.
Journal of Experimental Medicine, 185(4), 583-599.
Piddlesden, S. J., Lassmann, H., Zimprich, F., Morgan, B. P., & Linington, C.
(1993). The Demyelinating Potential of Antibodies to Myelin
Oligodendrocyte Glycoprotein Is Related to Their Ability to Fix
Complement. The American journal of pathology, 143(2), 555-564.
Quintana, F. J., Farez, M. F., Viglietta, V., Iglesias, A. H., Merbl, Y., Izquierdo, G.,
. . . Weiner, H. L. (2008). Antigen Microarrays Identify Unique Serum
Autoantibody Signatures in Clinical and Pathologic Subtypes of Multiple
Sclerosis. Proceedings of the National Academy of Sciences, 105(48),
18889-18894.
Ray, A., Mann, M. K., Basu, S., & Dittel, B. N. (2011). A Case for Regulatory B
Cells in Controlling the Severity of Autoimmune-Mediated Inflammation in
Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Journal of Neuroimmunology, 230(1-2), 1-9.
Robinson, W. H., Fontoura, P., Lee, B. J., Neuman de Vegvar, H. E., Tom, J.,
Pedotti, R., . . . Steinman, L. (2003). Protein microarrays guide tolerizing
DNA vaccine treatment of autoimmune encephalomyelitis. Nature
Biotechnology, 21(9), 1033-1039.

59

Rojas, J. I., Patrucco, L., Tizio, S., & Cristiano, E. (2012). Oligoclonal Bands in
the Cerebrospinal Fluid and Increased Brain Atrophy in Early Stages of
Relapsing-Remitting Multiple Sclerosis. Arquivos de Neuro-Psiquiatria,
70(8), 574-577.
Roucard, C., Thomas, C., Pasquier, M.-A., Trowsdale, J., Sotto, J.-J., Neefjes, J.,
& van Ham, M. (2001). In Vivo and In Vitro Modulation of HLA-DM and
HLA-DO Is Induced by B Lymphocyte Activation. Journal of Immunology,
167(12), 6849-6858.
Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P., & Yamaguchi, T. (2009).
Regulatory T cells: how do they suppress immune responses?
International Immunology, 21(10), 1105-1111.
Saxena, A., Martin-Blondel, G., Mars, L. T., & Liblau, R. S. (2011). Role of CD8 T
cell subsets in the pathogenesis of multiple sclerosis. FEBS Letters,
585(23), 3758-3763.
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004).
Detection of Ectopic B-cell Follicles with Germinal Centers in the
Meninges of Patients with Secondary Progressive Multiple Sclerosis. Brain
pathology, 14(2), 164-174.
Serres, S., Anthony, D. C., Jiang, Y., Campbell, S. J., Broom, K. A., Khrapitchev,
A., & Sibson, N. R. (2009). Comparison of MRI Signatures in Pattern I and
II Multiple Sclerosis Models. NMR in Biomedicine, 22(10), 1014-1024.
Simitsek, P. D., Campbell, D. G., Lanzavecchia, A., Fairweather, N., & Watts, C.
(1995). Modulation of Antigen Processing by Bound Antibodies Can Boost
or Suppress Class II Major Histocompatibility Complex Presentation of
Different T Cell Determinants. Journal of Experimental Medicine, 181(6),
1957-1963.
Sloka, S., Silva, C., Wang, J., & Yong, V. (2011). Predominance of Th2
Polarization by Vitamin D Through a STAT6-Dependent Mechanism.
Journal of Neuroinflammation, 8(1), 56.
Smolders, J., Thewissen, M., Peelen, E., Menheere, P., Tervaert, J. W.,
Damoiseaux, J., & Hupperts, R. (2009). Vitamin D Status is Positively
Correlated with Regulatory T Cell Function in Patients with Multiple
Sclerosis. PLoS ONE, 4(8), e6635.
Smyth, K. A. (2011). Cost-effectiveness analyses of treatments for multiple
sclerosis Are they clinically relevant? Neurology, 77(4), 317-318.
Steinman, L. (2014). Immunology of Relapse and Remission in Multiple
Sclerosis. Annual Review of Immunology, 32, 257-281.

60

Sundqvist, E., Sundström, P., Lindén, M., Hedström, A., Aloisi, F., Hillert, J., . . .
Olsson, T. (2012). Epstein-Barr Virus and Multiple Sclerosis: Interaction
with HLA. Genes and Immunity, 13(1), 14-20.
Tejera-Alhambra, M., Alonso, B., Teijeiro, R., Ramos-Medina, R., Aristimuño, C.,
Valor, L., . . . Sánchez-Ramón, S. (2012). Perforin Expression by CD4+
Regulatory T Cells Increases at Multiple Sclerosis Relapse: Sex
Differences. International Journal of Molecular Sciences, 13(6), 66986710.
Travis, M. A., & Sheppard, D. (2014). TGF-b Activation and Function inImmunity.
Annual Review of Immunology, 32, 51-82.
Tuohy, V. K., Yu, M., Yin, L., Kawczak, J. A., & Kinkel, R. P. (1999).
Spontaneous Regression of Primary Autoreactivity during Chronic
Progression of Experimental Autoimmune Encephalomyelitis and Multiple
Sclerosis. Journal of Experimental Medicine, 189(7), 1033-1042.
Urich, E., Gutcher, I., Prinz, M., & Becher, B. (2006). Autoantibody-mediated
demyelination depends on complement activation but not activatory Fcreceptors. PNAS, 103(49), 18697-18702.
van der Star, B. J., Vogal, D. Y., Kipp, M., Puentes, F., Baker, D., & Amor, S.
(2012). In Vitro and In Vivo Models of Multiple Sclerosis. CNS &
Neurological Disorders -Drug Targets, 11(5), 570-588.
Vanderlugt, C. L., Smith Begolka, W., Neville, K. L., Katz-Levy, Y., Laurence, H.
M., Eagar, T. N., . . . Miller, S. D. (1998). The functional significance of
epitope spreading and its regulation by co-stimulatory molecules.
Immunological Reviews, 164(1), 63-72.
Vartdal, F., Vandvik, B., Michaelsen , T. E., Loe, K., & Norrby, E. (1982).
Neurosyphilis: Intrathecal synthesis of oligoclonal antibodies to treponema
pallidum. Annals of Neurology, 11(1), 35-40.
Vidarsson, G., Dekkers, G., & Rispens, T. (2014). IgG subclasses and allotypes:
from structure to effector functions. Frountires in Immunology, 520(5), 117.
Viglietta,, V., Baecher-Allan, C., Weiner, H. L., & Hafle, D. A. (2004). Loss of
Functional Suppression by CD4 ? CD25 ? Regulatory T Cells in Patients
with Multiple Sclerosis. Journal of Experimental Medicine, 199(7), 971979.
Villar, L. M., Sádaba, M. C., Roldán, E., Masjuan, J., González-Porqué, P.,
Villarrubia, N., . . . Álvarez-Cermeño, J. C. (2005). Intrathecal Synthesis of
Oligoclonal IgM Against Myelin Lipids Predicts an Aggressive Disease
Course in MS. Journal of Clinical Investigation, 115(1), 187-194.

61

von Büdingen, H.-C., Hauser, S. L., Ouallet, J.-C., Tanuma, N., Menge, T., &
Genain, C. P. (2004). Epitope recognition on the myelin/oligodendrocyte
glycoprotein differentially influences disease phenotype and antibody
effector functions in autoimmune demyelination. European journal of
immunology, 34(8), 2072-2083.
Watts, C., & Lanzavecchi, A. (1993). Suppressive effect of antibody on
processing of T cell epitopes. Journal of Experimental Medicine, 178(10),
1459-1463.
Weber, M. S., Hemmer, B., & Cepok, S. (2011). The role of antibodies in multiple
sclerosis. Biochimica et biophysica acta, 1812(2), 239-245.
Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D., Ebers, G. C., & The
Canadian Collaborative Study Group. (2003). Twin concordance and
sibling recurrence rates in. PNAS, 100(22), 12877–12882.
Wilson, H. (2012). B Cells Contribute to MS Pathogenesis Through AntibodyDependent and Antibody-Independent Mechanisms. Biologics: Targets
and Therapy, 6, 117-123.
Wolf, S. D., Dittel, B. N., Hardardottir, F., & Janeway, C. A. (1996). Experimental
Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient
Mice. Journal of Experimental Medicine, 184(6), 2271-2278.
Wright, N., Laín de Lera, T., García-Moruja, C., Lillo, R., García-Sánchez, F.,
Caruz, A., & Teixidó, J. (2003). Transforming growth factor-β1 downregulates expression of chemokine stromal cell–derived factor-1:
functional consequences in cell migration and adhesion. Blood, 102(6),
1978-1984.
Yanaba, K., Bouaziz, J.-D., Haas, K. M., Poe, J. C., Fujimoto, M., & Tedder, T. F.
(2008). A Regulatory B Cell Subset with a Unique CD1dhiCD5+
Phenotype Controls T Cell-Dependent Inflammatory Responses.
Immunity, 28(5), 639-650.
Yin, L., Yu, M., Edling, A. E., Kawczak, J. A., Mathisen, P. M., Nanavati, T., . . .
Tuohy, V. K. (2001). Pre-Emptive Targeting of the Epitope Spreading
Cascade with Genetically Modified Regulatory T Cells During Autoimmune
Demyelinating Disease. Journal of Immunology, 167(11), 6105-6112.
Yong, V. W., Giuliani, F., Xue, M., Bar-Or, A., & Metz, L. M. (2007). Experimental
Models of Neuroprotection Relevant to Multiple Sclerosis. Neurology,
68(22 Suppl 3), S32-S37.
Yu, M., Johnson, J. M., & Tuohy, V. K. (1996). A Predictable Sequential
Determinant Spreading Cascade Invariably Accompanies Progression of
Experimental Autoimmune Encephalomyelitis: A Basis for Peptide-Specific

62

Therapy After Onset of Clinical Disease. Journal of Experimental
Medicine, 183(4), 1777-1788.
Zamvil, S., Nelson, P., Trotter, J., Mitchell, D., Knobler, R., Fritz, R., & Steinman,
L. (1985). T-cell clones specific for myelin basic protein induce chronic
relapsing paralysis and demyelination. Nature, 317, 355-358.
Zhang, N., & Bevan, M. J. (2013). Transforming growth factor-β signaling
controls the formation and maintenance of gut-resident memory T cells by
regulating migration and retention. Immunity, 39(4), 687–696.

